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3Abbreviations
cl: Lambda phage repressor protein, 12-26: cl residues 12 to 26, 12-
24: cl residues 12 to 24, etc., P12-26: the peptide corresponding to
residues 12-26 of cl, etc., WT: wild-type, IPTG: Isopropyl-thio-
galactoside, LB: Luria Broth, g: Immunoglobulin, CDR:
Complementarity Determining Region, TCR: T Cell Receptor, LMP: Low
Molecular weight Polypeptide, ER: Endoplasmic Reticulum, li:
Invariant Chain,
4Introduction
The capacity of the immune system to respond to foreign
pathogens depends upon its ability to produce cells bearing an
enormous diversity of receptors which can bind these pathogens at
high affinity. At the same time, in order to avoid autoimmunity, the
immune system must eliminate or render non-responsive all cells
bearing receptors capable of reacting with self proteins. In order to
do this an elaborate system of regulation has evolved, with
separate, but related mechanisms for dealing with each of the two
principal classes of pathogens: extracellular, such as bacteria or
toxins, and intracellular, such as viruses or tumor-inducing gene
products.
For intracellular pathogens, the goal is to eliminate cells
harboring the pathogen. Proteins expressed by infecting viruses or
involved in tumor production are "processed" intracellularly into
peptide fragments which are bound specifically by MHC Class I
proteins, and are displayed on the cell surface. These complexes are
recognized and the cells are eliminated by a subset of T lymphocytes
expressing the co-receptor CD8 (Townsend and Bodmer, 1989). This
permits them to specifically recognize Class I molecules.
In order to be able to respond to the full diversity of antigens
which the immune system will face, the receptor by which T cells
recognize these peptide-MHC complexes (the T cell receptor or TCR)
has a binding site for antigen which is assembled randomnly from
several genes, as is the case for immunoglobulins (Davis and
Bjorkman, 1988). Several similar models have been proposed for the
structure of the TCR based on the structure of immunoglobulins
(Chothia, et al., 1988; Claverie, et al., 1989; Davis & Bjorkman,
1988). This parallel is based on the observation that a great many
elements previously found to be unique to the structure of
antibodies also appear in the TCR. Crystal structures of antibodies
show close intra- and inter-chain contacts at many positions (Amit,
et al., 1986; Amzel, et al., 1974; Amzel and Poljak, 1979; Colman, et
al., 1987). The residues participating in these contacts are
conserved between different antibody sequences, (Chothia, et al.,
1985; Novotny and Haber, 1985) and many of these residues are also
conserved in TCR sequences (Becker, et al., 1985; Chothia et al.,
1988; Novotny, et al., 1986).
As for immunoglobulins, the predicted combining site of the
TCR is formed by three separate Complementarity Determining
Regions (CDRs), two of which are formed by the products of the Va
and V genes, with a third being encoded by sequences lying at the
junctions of the Va and J, and Vp, Dp, and J genes. TCR genes,
unlike immunoglobulin genes (Tonegawa, 1983), do not undergo
somatic hypermutation in the periphery (Chien, et al., 1984; Hayday,
et al., 1985). This has the important consequence that T cells
emerging from the thymus after maturation (described below) do not
change their specificity.
In terms of its implications for antigen recognition, the most
important structural difference between immunoglobulins and the
TCR is that a much greater part of the diversity between TCRs lies
in the CDR3 compared to what is the case in immunoglobulins. While
6there are estimated to be 62,500-250,000 possible combinations of
VL and VH for immunoglobulins, there are only about 1/100 this
many possible combinations of Va and Vp for the TCR (Davis &
Bjorkman, 1988). By contrast, because of a greater number of J
elements, and insertion of non-germline-encoded N-region additions
in the junctions, the TCR has an estimated 1015 possible junctional
combinations, while immunoglobulins have only 1011 (Davis &
Bjorkman, 1988). The TCR is specialized for recognition of the
complex of a relatively non-diverse MHC molecule binding peptides
which can be quite different from one another. Current models all
hold that these junctional regions (CDR3) are primarily responsible
for interaction with peptide antigen, and the V gene-encoded
residues are responsible for recognition of the MHC molecule. This
model is supported experimentally by the observation that
correlations can be found between the fine-specificity of T cells for
peptide antigens, and sequences in their junctional regions (Danska,
et al., 1990; Engel and Hedrick, 1988; Jorgenson, et al., 1992; Lai, et
al., 1990). An MHC interaction site has been mapped to CDRs 1 and 2
(Hong, et al., 1992).
One consequence of this mechanism for generation of diversity
is that some TCRs will recognize self-antigen. In order to avoid
responding to self, cells bearing these receptors undergo a
maturation process in the thymus. In a first step, termed negative
selection, cells expressing receptors which can recognize complexes
of peptides derived from endogenous antigen bound by Class I are
eliminated (Kisielow, et al., 1988; Teh, et al., 1988). It is not clear
against what percentage of proteins from the entire organism
7selection occurs at this stage. Theories predict that part of the role
of the thymus is to express all proteins at low levels to permit
tolerance (Lo, et al., 1989; Matzinger and Guerder, 1989; Moraham, et
al., 1989). However, it is known that albeit more poorly
characterized mechanisms also exist in the periphery to tolerize
cells, so this may not be necessary (Arnold, et al., 1992; Jones, et
al., 1990; Rocha and Von Boehmer, 1991).
The second step is positive selection where T cells are
permitted to proliferate if they have a certain minimum reactivity
with the self MHC molecule itself (Kisielow et al., 1988). In this
case, various theories predict either that the T cell receptor is
recognizing an "empty" MHC class I molecule, or an MHC molecule
containing specialized peptides dedicated to positive selection
(Marrack and Kappler, 1988; Marrack, et al., 1989; Nikolic-Zugic and
Bevan, 1990). By these means, T cells leaving the thymus are
expected to have a certain minimum specificity for the MHC
molecules expressed in the organism, but not one which is sufficient
for activation. Additional interactions between the TCR and
peptides derived from pathogens presented by these molecules would
then provide the additional affinity necessary for activation of the T
cell.
In order to produce the peptides which can bind MHC class I and
introduce them to the compartment where they can interact with
these proteins, both in the thymus and in periphery, an additional
elaborate system exists. It appears that proteins must first reach
the cytoplasm (Monaco, 1992). Prevailing opinion is that they are
then digested by a protease or proteases which have not been
8identified, and the sequence specificity of which has not been
characterized. A likely candidate for this protease is the so-called
Low Molecular Weight Polypeptide complex (LMP). Its role is
suggested by the fact that it possesses proteolytic activity, and at
least two of its subunits map to a region of the MHC known to be
important for antigen processing (Brown, et al., 1991; Kelly, et al.,
1991; Martinez and Monaco, 1991; Monaco and McDevitt, 1982;
Monaco and McDevitt, 1984; Monaco and McDevitt, 1986). However,
there is no direct evidence implicating it in antigen processing.
Subsequently, according to current models, these peptides are
transported across the membrane of the ER. This function is most
likely carried out by a heterodimer of the products of two genes,
known variously as mtp 1, mtp2, RING1, RING4, PSF1, PSF2, HAM1,
HAM2, and in a new unified nomenclature as TAP1 and TAP2
(Deverson, et al., 1990; Monaco, et al., 1990; Spies, et al., 1990;
Trowsdale, et al., 1990). The piece of good fortune that permitted
their identification by these means is that most Class I molecules
are unstable and become rapidly degraded if they reach the cell
surface without bound peptide (Ljunggren, et al., 1990; Townsend, et
al., 1989). Thus, screening for lack of class I expression identified
cells that could not transport peptides across the ER membrane.
Cells with a deletion of only one of these genes are still able to
present some peptides, which indicates that a heterodimer
constitutes the normal functional protein, and that a homodimer may
retain some function (Hosken and Bevan, 1992). Once peptides have
gained entry to the ER by these transporters they can presumably
bind MHC class I and be brought to the cell surface by the normal
9surface membrane protein pathway. It is important to note that
there is no direct evidence to support the theory that proteolysis
occurs prior to translocation. It remains possible that translocation
occurs first and proteolysis occurs within the ER. Indeed, one report
has demonstrated that cells transfected with a protease for
expression within the secretory pathway are more efficient at
presentation of some peptides expressed in the cytoplasm
(Eisenlohr, et al., 1992). Futhermore, in these transfected cells,
peptides as long as 32 amino acids were transported from the
cytoplasm and trimmed within the ER. The most important piece of
evidence suggesting that proteolysis does occur before transport is
that peptides derived from proteins in the secretory pathway can be
eluted from Class I molecules in TAP mutants, but have lengths that
vary widely from those eluted from wild-type cells (Henderson, et
al., 1992). This suggests that these peptides are not produced by the
same proteases responsible for the digestion of the peptides bound
to Class I molecules in normal cells. Peptides which enter the ER by
other pathways can also bind MHC. For example, peptides preceded
by a leader that allows them to enter by the normal SRP pathway can
sensitize TAP mutant cells for lysis by T cells (Anderson, et al.,
1991).
That the ER is the meeting point for antigen and class I
explains the observation that presentation of Class I-restricted, but
not Class Il-restricted antigen can be blocked by the drug Brefeldin
A (BFA) (Nuchtern, et al., 1989). BFA inhibits transport into the cis-
Golgi, and collapses the Golgi (Pelham, 1991). Thus, peptide
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antigens and MHC that meet in the ER cannot be transported to the
surface and be presented.
Binding to MHC molecules is a specific interaction, of a
classical ligand-receptor type. The crystal structure of the MHC
class I molecule has been solved (Bjorkman, et al., 1987a). It
contains a deep antigen binding groove formed by a-helices with a 3-
sheet floor. The molecule is highly polymorphic, and the
polymorphic residues are concentrated around this groove thus
giving different molecules different peptide-binding specificities
(Bjorkman, et al., 1987b; Parham, 1988).
Several studies have shown that class I molecules
preferentially bind peptides of length 9+l1 aa (Cerundolo, et al., 1991;
Schumacher, et al., 1991; Tsomides, et al., 1991). In general class I
molecules show very high specificity for binding peptides containing
specific amino acids at particular positions (Falk, et al., 1991;
Rotzschke and Falk, 1991). The preferred amino acids and their
relative position are different for each Class I protein, and
constitute motifs that appear to be shared among among all peptides
that bind the same Class I.
The peptide-Class I complex, once it has reached the surface,
can be recognized by CD8 positive T cells. In this case the cell is
then killed (Taylor and Cohen, 1992).
For the class I antigen presentation pathway, several
important questions remain to be anwered, among them: How is it
that proteins which are not expressed in the cytoplasm, such as
nuclear proteins can be presented? Do there exist dedicated
pathways to bring peptides derived from these proteins to the ER, or
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does presentation depend upon a "leakiness" of the expression of
these proteins into the cytoplasm? Is the proteosome indeed
involved in antigen processing? What is the peptide specificity of
enzyme involved in processing? Is processing completed in the
cytoplasm, or is some sort of trimming of peptides required in the
ER to produce the mature peptides which bind to MHC? How does one
account for the tight limitation in sizes of peptides which are found
bound to Class I? Does this indicate that processing enzymes tend
to produce peptides of this length, or are a variety of peptides
produced, and selection performed at the level of binding to Class I?
Besides the TAP proteins, Class I proteins and proteases, what
additional proteins are involved in processing? Two genes coding
for members of the hsp70 family have been found in the MHC
suggesting that a chaperone function may be necessary (Sargent, et
al., 1989). Finally, it is important to determine the nature of
peptides bound in the groove of Class I proteins during negative and
positive selection, whether these are all peptides from the
organism, none, or special peptides dedicated to these functions.
T cells specific for exogenous pathogens express CD4 and
recognize antigen bound by class II molecules (Parnes, 1989). They
use the same genes to form their T cell receptors and undergo a
similar process of maturation involving positive and negative
selection in the thymus. The principle differences between the two
classes of cells are their effector mechanisms, and the pathways by
which antigen is processed and presented to them. Recognition of
the class-ll/peptide complex by CD4-positive T cell leads to
stimulation of T cell help in the form of interleukin secretion
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necessary for the maturation of immature B cells into antibody-
producing plasma cells (Vitetta, et al., 1989), and in other cases,
probably to forms of help necessary for stimulation of CD8-positive
T cells. (Fayolle, et al., 1991; Guerne, et al., 1984; Mizuochi, et al.,
1986).
The peptides presented by class II molecules can come from a
greater diversity of sources than is the cases for class I-restricted
antigens (Brodsky and Guagliardi, 1991). The most classical is the
endocytic route. The necessity of internalization for processing and
presentation of protein antigens is demonstrated by the fact that
fixation of cells by formaldehyde blocks presentation of intact
proteins, but not peptides (Unanue, 1984). Entry into the endocytic
pathway can occur either by internalization of antigen bound to
surface immunoglobulin on B cells (Lanzavecchia, 1990), or by fluid
phase endocytosis (Unanue and Allen, 1987). In either case,
internalized antigen is directed to early endosomes. This
compartment contains the proteolytic enzymes Cathepsin B and D
which have been implicated in processing (Diment, 1990; Shaw and
Chain, 1989; Takahashi, et al., 1989). Processing of protein antigen
is therefore believed to occur at this stage, although whether it can
be completed may depend upon the antigen. Recently, a third enzyme,
Cathepsin E, has been implicated in processing (Bennett, et al.,
1992), and localized to a non-lysosomal compartment of the
endosomal system, i.e. perhaps the early endosome.
Although a great deal of evidence indicates that the specific
sites of cleavage of a protein play an important role in which
sequences within a protein are antigenic, the sequence specificity of
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these enzymes has not yet been well characterized (Bond and Butler,
1987). This evidence includes the observation that presentation of
some epitopes, but not others within a protein, is reduced by
inhibitors of various proteases, again, particularly members of the
Cathepsin family (Bennett et al., 1992; Diment, 1990; Takahashi et
al., 1989; Vidard, et al., 1991).
The optimum pH for these enzymes is approximately 5.5, and
proteolysis may be facilitated by denaturation of proteins caused by
a gradual acidification that occurs during transport toward
lysosomes (Mellman, et al., 1986). Class II presentation is
abrogated by ammonium chloride or chloroquine (Ziegler and Unanue,
1982), drugs that raise the pH of intracellular compartments. Cells
that are mutant for endosome acidification also have diminished
presentation of Class Il-restricted antigens (McCoy, et al., 1989).
The intracellular location where peptide antigens bind Class II
molecules remains controversial. Three studies using techniques of
subcellular fractionation indicate that the endocytic pathway
intersects the transport pathway of Class II molecules in the early
endosome (Guagliardi, et al., 1990; Lamb, et al., 1991; Lotteau, et al.,
1990). However, a more recent one using electron microscopy
indicates that it occurs in a post-Golgi compartment related to
lysosomes (Peters, et al., 1991). Another study used specially
composed liposomes to target protein antigens to lysomes bypassing
endosomes, and found that they were processed efficiently, recycled
and presented to T cells (Harding, et al., 1991). Furthermore, the
efficiency of presentation was higher than for protein antigens
delivered directly to endosomes. This indicates that protein
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antigens can be degraded in a compartment late in the endocytic
pathway and their processing products can come in contact with MHC
Class II molecules. It also suggests that for some antigens, such a
step may be necessary for complete processing. The reasons for the
different conclusions obtained in the references cited above are not
clear, but all studies are in agreement with the conclusion that
peptides derived from protein antigens come in contact with Class II
molecules via the endocytic pathway.
As the initial pathways followed by class I and class II
molecules are identical, it is important that a means exist to
prevent the saturation of class II molecules by peptides in the ER
and Golgi. Otherwise, Class II molecules would not be able to
present exogenous antigens. This role appears to be played by the
Invariant Chain (li). The Invariant chain has been shown to bind
Class II dimers in the rough ER following their synthesis, probably
forming a nine protein complex (Marks, et al., 1990; Roche, et al.,
1991). Class Il-li complexes are unable to bind peptides in vitro
(Roche and Cresswell, 1991a), and cells expressing a secreted
version of Ii have a diminished capacity to present peptides in vitro
(Teyton, et al., 1990).
The Invariant chain has also been implicated in the targeting
of Class II to the endosomal pathway. Transfected cells expressing
only Class II - and 3-chains transport the assembled molecules to
the cell surface (Peterson and Miller, 1990; Sekaly, et al., 1986).
However, this is probably due to the normal transport of all proteins
in the exocytotic pathway via the Golgi that occurs by default
(Rothman, 1987). This conclusion is based on the observation that
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cells transfected only with Class II stain for expression in the ER,
Golgi and on the cell surface, whereas cells co-transfected with i
also stain for Class II in endosomes (Lotteau et al., 1990). The
pathway by which Class II reaches endosomes in the co-
transfectants has been examined by pulse-chase experiments. It
does not appear to occur by transport to the surface and re-
internalization (Lotteau et al., 1990). In the absence of Class II
expression, li is retained in the ER (Bakke and Dobberstein, 1990;
Lotteau et al., 1990). Experiments involving transfection of cells
with truncated variants of Ii lacking the N-terminus indicate that
this is due to an ER retention signal lying in the cytoplasmic
extension (Bakke & Dobberstein, 1990; Lotteau et al., 1990). Binding
to aoc dimers apparently suppresses this signal and allows a second
one targeting it to the endosome to dominate. Truncated variants of
i lacking the ER retention signal also seem to be transported
directly to the endosome. The signal for li to dissociate from the
Class II molecule to permit binding of peptides appears to be induced
by its cleavage by proteases in the endosome (Blum and Cresswell,
1988; Machamer and Cresswell, 1984; Nguyen, et al., 1989; Nowell
and Quaranta, 1985) It has been demonstrated that intact Class II
molecules capable of binding peptide are released from li by in vitro
digestion by Cathepsin B (Roche and Cresswell, 1991b). Thus Ii can
protect Class II molecules from becoming saturated with
intracellular peptides before coming in contact with exogenous
peptides in this compartment. At this time it is not clear by what
pathway peptide-Class II complexes are transported to the cell
surface.
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The purification and sequencing of peptides bound to Class II
molecules has been achieved more recently than for Class I-bound
peptides (Rudensky, et al., 1991). There are several characteristics
that distinguish the two types. First, the Class I molecule has been
shown to preferentially bind peptides of a defined length (Cerundolo
et al., 1991; Schumacher et al., 1991; Tsomides et al., 1991), while
Class II molecules are apparently capable of binding peptides
varying greatly in size. This is reflected by the observation that
typical peptides eluted from Class I molecules are approximately 9
amino acids (Falk et al., 1991; Rotzschke & Falk, 1991), while those
eluted from Class II molecules range from 13-17 amino acids (Hunt,
et al., 1992; Rudensky, et al., 1992; Rudensky et al., 1991). Second,
several different truncated variants of the same peptide are found
bound to Class II molecules (Hunt et al., 1992; Rudensky et al., 1992;
Rudensky et al., 1991), whereas a given peptide bound to Class I
molecules in normal cells has always been found to have the same N-
and C-termini (Falk et al., 1991; Rotzschke & Falk, 1991). Once
again, in the case of Class I molecules, this appears to reflect a
preference for peptides of a defined length, as well as a particular
positioning of the key amino acids constituting the Class I-binding
motif within the groove. It may also partly reflect the role of
antigen processing and selectivity of transport of certain peptides
into the ER by TAP proteins. Peptides eluted from Class II molecules
have different N- and C-termini suggesting that the proteins they
are derived from are first digested into relatively long peptides, and
that these peptides are subsequently trimmed to the mature
peptides found bound to the Class II molecule. Although motifs have
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been identified for binding to Class II molecules by sequence
comparison of epitopes having the same restriction, and by in vitro
binding experiments, they are generally less precisely defined and
less stringent than those identified for Class I binding. For example,
motifs for Class I binding are generally constituted of two or three
particular amino acids with a fixed separation within the sequence.
By contrast, the motif for binding the Class II Ad molecule, which
has now been verified by elution and sequencing of peptides (Hunt et
al., 1992), has relatively low stringency with respect to
substitutions at each position, but is six amino acids long (Sette, et
al., 1989; Sette, et al., 1988). Thus although the Class II protein is
considered to be structurally similar to Class I (Brown, et al.,
1988), there appear to be fundamental differences in the way the
two bind peptides, and in the nature of the peptides bound by each.
As is the case for the Class I antigen presentation pathway, a
number of important questions remain for the Class II antigen
presentation pathway. The most elusive of these have to do with the
mechanism of peptide generation from exogenous protein. Although
various proteases have been implicated, no conclusive evidence has
been found for the involvement of any one in particular. If members
of the Cathepsin family are involved in processing, it is not known if
the peptides produced from their action are the mature peptides
found bound to Class II molecules, or whether trimming is required.
There are several examples of sequences within proteins which are
capable of binding MHC and stimulating T cells if immunization is
with peptide, but to which there is no response if the intact protein
is used. One would therefore like to identify definitively the sites
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of proteolysis necessary for presentation of a given epitope as
means of determining the role processing plays in the hierarchy of
epitopes within a protein. It remains unclear in which compartment
processing occurs, the endosome, or the lysosome. It may be that
processing and transport to compartments containing Class II
molecules is a continuous and progressive process. Some epitopes
may be produced by the relatively mild proteolytic conditions in the
early endosome, whereas others may require more extensive
proteolysis in the late endosome or lysosome. The possible role of
other proteins, such as chaperonins, remains to be investigated.
More extensive analysis of the binding of peptides to Class II
molecules is required. Beyond this, one would like to know the
reasons for differences in the peptides bound by Class II and Class I
antigens. Finally, the molecular means by which the peptide-MHC
complex is recognized by the T cell receptor requires further
investigation. The degree to which the functions of MHC- and
peptide-recognition are divided between different domains of the
TCR requires further clarification. Such knowledge is ultimately
essential for a complete understanding of the molecular basis for
positive and negative selection of T cells in the thymus, and will be
useful in determining how to improve the immune response to
foreign pathogens.
The work described here was performed in order to understand
the respective roles of antigen processing, presentation and T cell
recognition in response to a single Class Il-restricted epitope. The
epitope chosen was that which was previously identified as the
immunodominant epitope from the protein X-repressor (cl) in d-and
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k-haplotype mice (Lai, et al., 1987). In the first chapter we analyze
the binding of the peptide to the Class II Ek molecule, and determine
the critical residues in the peptide sequence involved. In the second
chapter, we describe the response of a panel of T cells to the
epitope, identify the key residues for their response, and identify
correlations between responsiveness of the cells and conserved
elements in the sequences of their TCR genes. Finally, in the third
chapter we examine the role of the residues outside the epitope in
the processing of the epitope in attempt to determine the structural
cues in the protein which are important for proper proteolysis, and
identify proteins which are processed less efficiently than the
wild-type.
20
Materials and Methods
Cell lines
T cell hybridoma A128, is Ad-restricted and specific for
residues 46-62 of cl. It was a gift from Dr. Francesco Ria
(Universita Cattolica, Rome, Italy). Hybridoma IG6.4, specific for
Hen Egg Lysozyme residues 1-14, and 2H6.41, specific for HEL
residues 105-120, both Ek-restricted, were from Dr. Serge Fuchs,
Sandoz Ltd., Basel, Switzerland. Ek-restricted hybridomas 31, 41, 81,
101 (Lai et al., 1987; Lai, et al., 1988) were from Dr. Ming-Zong Lai,
Institute of Molecular Biology, Taipei, Taiwan. All other 12-26-
specific T hybridomas described here were produced by A.S. using
the technique previously described by Lai et al. (1987). The fusion
partner was the TCR-deleted thymoma line BW5147a-p- (White, et
al., 1989). Ek-restricted hybridomas described in Chapter 2 were
produced from CBA mice. The Ad-restricted cells 24.4 and 26.2 were
produced from Balb/c mice. Cell 26.2 was produced by immunisation
with peptide 12-26 and cell 24.4 by immunisation with peptide 12-
24. The antigen presenting ell line TA3 (I-Ad/k, Ed/k) was from Dr.
L. Glimcher, Harvard University. The IL-II/IV-dependent cell line
CTL.L2 was from Dr. D. Raulet, University of California, Berkeley.
All cell lines were grown and assays carried out using complete
RPMI 1640 medium (RPMI 1640 (Seromed, France) with 10% fetal
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calf serum, 2501gg/ml glutamine, 100 g/ml penicillin and 621tg/ml
streptomycin).
Measurement of T Hybridoma Response to Peptides and Proteins
Assays of this type were conducted in 96-well plates using
serial dilutions of antigens. Each well contained 2.5X104 T cells
and 104 TA3 as APC in a volume of 1001. Cultures were incubated
for 18-24 hours before assay of interleukin secretion. To assay
hybridoma supernatants for interleukin content, 501gl of the
supernatant was transfered to a second plate which was frozen for
two hours at -80°C and thawed at 37°C. 104 CTL.L.2/well were
added in 50p of complete RPMI. 18 hours later, 0.5pzCi/well of
tritiated thymidine (Amersham) was added. After further incubation
for 6 hours, the cells were harvested onto glass fiber filters and
thymidine incorporation measured using a Skatron 96-well harvester
and an LKB Beta-Plate scintillation counter.
Competition Binding Experiments
Serial two-fold dillutions of competitor peptides (in general,
analogs of P12-26) were prepared in complete RPMI along rows of
96-well plates. Each well contained 2511. Subsequently, 25g of
glutaraldehyde-fixed (see below) TA3 cells were added at a
concentration of 4X105 cells/ml, and the plates were incubated at
370 for six hours to allow peptides to bind Ek. At this time, a fixed
concentration of an un-related Ek-restricted stimulator peptide was
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added to all wells in 5011 along with 2.5X104 T cells specific for
this peptide. The concentration of the stimulator peptide to be used
was in each case determined two days previous to the competition
experiment as that which induced 75% maximal stimulation in the
absence of competitors. The stimulator peptide used for the
experiments described in Chapter 1 was HEL 1-14, or HEL 105-120,
and the T hybridomas used were IG6.4, or 2HG.41, respectively. The
plates were incubated for a further 18 hours, and frozen for 2 hours
below -800C. After thawing at 370C, supernatants were assayed for
interleukin content by measuring thymidine incorporation in the
CTL.L assay described above. The relative effectiveness of peptides
as competitors was determined as the concentration of P12-26
necessary to reduce stimulation of the appropriate T cell by 50%
divided by the concentration of a given analog necessary to achieve
the same effect. To confirm that a reduction in stimulation of was
not due to toxicity of the peptide, experiments were conducted
where the competitor peptide was added subsequently to the
stimulator peptide. Under these conditions, no significant inhibitory
effect was observed for any peptide.
Glutaraldehyde Fixation of Antigen Presenting Cells
TA3 cells were washed three times by centrifugation and
resuspension in PBS and resuspended PBS with 0.05% glutaraldehyde
(Sigma). The cells were incubated 60 seconds after which a five-
fold volume excess of 0.25 M HCI-lysine in PBS was added to quench
glutaraldehyde. After washing twice in PBS, the cells were
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resuspended at 2X105/ml in complete RPMI. Cells fixed by this
method are as effective for presentation of P12-26 as un-fixed TA3
cells. Intact cl protein is not processed by fixed APC, and was used
as a positive control for fixation.
Peptides and Proteins
P12-26 and truncated analogs were synthesized in the
laboratory of Dr. A.D. Strosberg, Institut Cochin de G6n6tique
Moleculaire, Paris, France using an Applied Biosystems apparatus.
Analogs of P12-26 containing single substitutions were a gift of Dr.
F. Borras-Cuesta, Pamplona, Spain. cl protein, and variants
containing substitutions were purified from E. coli according the
previously described procedure (Johnson, et al., 1980).
Strains and plasmids
Propagation of plasmids was conducted in the F'laclQ E. coli
strain X90 (Hanahan, 1983). Expression of cl and cl mutants was
carried out in X90 carrying the plasmid plys-s (Studier, et al.,
1990). This plasmid contains the gene encoding lysozyme, and cells
carrying it are thus susceptible to lysis by freeze-thaw. The
plasmids pAS101 and pAS102 carry the cassette gene for the entire
coding sequence of cl. They were made by ligating the small Pvu I-
EcoRI fragment of plasmids pWL103 and pWL105, respectively
(Reidhaar-Olson and Sauer, 1990) into the backbone of plasmid
pRB200 (Breyer and Sauer, 1989). The pWL plasmids were a gift of
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Dr. Robert Sauer (MIT), and pRB200 was a gift of Dr. Richard Breyer,
(Vanderbilt University). pAS101 differs from pAS102 in that it
contains an Ncol site overlapping codon 1 in order to permit
mutagenesis at the N-terminus and thus codes for glycine at residue
1 instead of the wild-type serine. The wild-type amino acid is
reintroduced during mutagenesis.
Cassette mutagenesis
The procedure of Oliphant (Oliphant, et al., 1986) was used to
generate mutations at one to four codons at a time in the cl gene.
For this purpose pAS101 or pAS102 was digested with two
restriction enzymes, one on either side of the desired site of
modification. The short fragment produced was replaced by a
synthetic oligonucleotide cassette. One oligonucleotide of each pair
was synthesized using an equimolar mixture of all four bases at
each mutagenized position. The complementary oligonucleotide
contained inosine residues at the corresponding positions. Synthesis
for mutagenesis at position 20 and 24-27 was performed using an
Applied Biosystems 391 apparatus. Other oligonucleotides were
obtained from the laboratory of Dr. Robert Sauer (MIT). For
mutagenesis at positions 8-11 an Ncol site in pAS101 beginning 4
bases upstream of the the first codon and a BssHII site beginning at
codon 15 were used. For mutagenesis C-terminal to position 17 the
BssHII and Sacl sites in pAS102 were used.
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Induction of Protein Expression and Preparation of Lysates
Individual colonies carrying cl variants were picked and grown
overnight in LB with 100M ampicillin and 251iM chloramphenicol.
50 1 of the saturated cultures were diluted into 10 ml of LB and the
cultures were grown with rotary agitation until one being monitored
reached an OD600 of cl. IPTG (Sigma) was then added to a final
concentration of 500p.M. Three hours later the bacteria were spun
down at 4000 RPM for 10 minutes in a Jouan GR412 centrifuge
resuspended in 1ml of RPMI tissue culture media and transferred to
microcentrifuge tubes. Lysis of the bacteria was performed by three
cycles of freezing in liquid nitrogen and thawing at 230C. In some
early experiments lysis was performed by sonication using a Sonics
and Materials sonicator (Danbury, Conn.) Debris was spun down at
10,000 RPM and supernatants were kept.
Screening of Lysates Containing cl Variants
10 1 of each lysate was added per well in a microtiter plate
containing 5X104 TA3 cells (Walker, et al., 1982) and 1X105 of the
appropriate T cell in 1001l of complete RPMI. 100pgg/ml Gentamycin
was included to reduce the risk of contammination from any
remaining live bacteria in the lysate. 18-24 hours later 50gl of
each supernatant was transferred to a second microtiter plate and
assayed for interleukin content by thymidine incorporation in CTL.L
cells.
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Chapter 1
Abstract
The epitopes recognized by T cells are peptides specifically
bound by molecules of the Major Histocompatibility Complex. In a
number of cases sequence motifs have been proposed which are
necessary for the binding of different peptides which can be
presented by the same MHC molecule. In order to determine the
critical residues for binding of 12-26 to the Ek-molecule, we
conducted competition binding experiments using a set of 63 analogs
differing from 12-26 by single substitutions. The results indicate
that binding of 12-26 to Ek is primarily due to interactions between
the MHC molecule and residues 18 and 26 of the peptide. These
residues correspond to those most conserved among other Ek-
restricted peptides. We propose a simplified Ek-binding motif that
consists of a basic residue (preferably a lysine) preceeded variably
7-8 residues before by a hydrophobic amino acid. Binding of
peptides to Ek may therefore be similar to binding to class I
molecules which have recently been shown to recognize two
principal anchor residues at the extremities, but to accomodate a
variable number of intervening residues. Substitutions at nearly
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every other position do generally affect binding to some extent. The
effect tends to be negative, as no example was found where a
substitution appeared to significantly increase binding to MHC.
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Introduction
Recognition of peptide antigens by T cells can essentially be
subdivided into two independent problems, binding of the peptide to
MHC, and recognition of the peptide-MHC complex by the TCR.
The first of these two essential steps can be thought of as a
classical ligand-receptor binding interaction. Class II molecules
have been demonstrated to have a unique binding site (Guillet, et al.,
11986), and peptides restricted by the same class II molecule have
been shown to compete for binding against one another both in
functional assays (induction of interleukin secretion by T cells)
(Guillet et al., 1986) and in direct binding experiments (Babbitt, et
al., 1986). Similar observations have been made for class I
molecules (Maryanski, et al., 1988; Pala, et al., 1988). The Kd for
the binding of various peptides to class II molecules has been
measured and is typically on the order of 1M (Babbit, et al., 1985).
Several attempts have been made to identify sequence patterns
or secondary structures common to all T cell epitopes that might be
required for binding to MHC. Different groups have found that
sequences consistent with 3-sheet (Spouge, et al., 1987), a-helical
(Allen, et al., 1987; Rothbard, et al., 1988) and in particular
amphipathic a-helical structures (De Lisi and Berzofsky, 1985;
Margalit, et al., 1987) exist in many epitopes and would correlate
with the distribution of la-contact and TCR residues in a peptide.
One group identified a short sequence pattern that was common to T
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cell epitopes of several different MHC restrictions (Rothbard and
Taylor, 1988).
A variety of evidence now suggests that no such general
structures are necessary for a sequence to become a T cell epitope,
and that specific sequences which vary depending upon the MHC
restriction of a given peptide play a more important role. The first
of these showed that proline or glycine residues could be introduced
into an epitope from ovalbumin without affecting its ability to bind
MH-IC (Sette, et al., 1989), thus making it unlikely that strict a-
helical or -sheet conformations are necessary. Other groups have
shown that peptides incorporating a few crucial residues into either
polyalanine (Jardetzky, et al., 1990), or polyproline or polyglycine
(Maryanski, et al., 1990) backbones can bind efficiently to MHC.
The crystal structure of the human class I molecule HLA-A2
has been solved (Bjorkman et al., 1987a). It contains a long groove
25A in length by about 10oA in width bounded by a-helices containing
the majority of the residues which are polymorphic between class I
molecules. This groove, which is the nominal antigen binding site,
would not be wide enough to accept a peptide in a-helical
conformation, but could do so in extended conformation (Claverie et
al., 1989). Although the structure of the class II molecule has not
been solved, a hypothetical model based on sequence homologies
suggests that it has a similar antigen binding site.
More recently, the structure of other class I molecules has
been determined, and in one case has been shown to contain a
nonamer peptide in extended conformation in its binding site
(Madden, et al., 1991). These studies have permitted the
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identification of unique pockets in the structure of individual class I
molecules that are probably responsible for their specificity of
binding (Garrett, et al., 1989). Peptides eluted from a given class I
molecule have been shown to contain conserved residues at two or
three positions in their sequences (Falk et al., 1991; Jardetzky, et
al., 1991). Modeling studies indicate that the conserved residues
would fit well into the specificity pockets of the class I molecule.
The other residues have a high degree of variability, indicating that
it is primarily the interaction of the MHC molecule with the primary
structure of peptides that determines binding. It is thus likely that
the conformation of the bound peptide is largely imposed on it by the
MHC molecule.
Peptides bound by class II molecules are much more
heterogeneous in sequence and length than those binding class . No
sequence motifs or apparent critical binding residues could be
identified in the first peptides eluted from class II molecules
(Rudensky et al., 1991). More extensive analysis has revealed such
motifs, but in general their stringency is significantly less than for
class I-binding peptides (Hunt et al., 1992; Kropshofer, et al., 1992;
Rudensky et al., 1992).
The most successful means of identifying motifs for class II
binding have been the comparison of sequences from various minimal
peptides binding the same class II molecule (Sette et al., 1989) and
the identification of critical residues in epitopes using substituted
peptides. This was originally performed in either direct binding
(Sette, et al., 1987), or competition binding experiments (Allen et
al., 1987) using alanine-substituted peptides.
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Previous studies have been conducted to determine the
shortest derivitive of P12-26 capable of binding Ek (Sette, et al.,
1989). Direct binding experiments using truncated variants of P12-
26 indicate that the C-terminal lysine is essential for Ek-binding.
The effect of truncations at the N-terminus is less clearcut.
Removal of the amino acids at positions 16-18 leads to a
progressive loss of binding. Here, in order to produce a more
detailed description of binding of P12-26 to Ek with specific
identification of the requirements and tolerance for charge, size and
hydrophobicity of amino acids at each position, we have employed a
set of 63 analogs of P12-26 containing single substitutions. By
examination of the effectiveness of each of these peptides in
competition binding experiments, and comparison to sequences of
other Ek-binding peptides we propose a refined model, involving only
two principle contacts between the peptide and MHC, for the binding
of peptides to Ek in general.
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Results
In order to identify MHC contact residues within P12-26,
competition binding experiments were performed using a large panel
of substituted analogs of P12-26. In general 5 different
substitutions were made at each position from residue 14-26 in
order to test not only whether a given residue was essential for
binding, but also to probe the chemical environment in its
interaction with the MHC molecule. Substitutions at positions 12
and 13 were not made because previous work has shown that
removal of these residues has no effect on the capacity of the
peptide to bind Ek. The substitutions made were to aspartate,
leucine, lysine and tyrosine. In addition, each position was also
substituted with alanine which is generally considered the
substitution causing the most minor perturbation of protein
structure. If the normal amino acid at a given position was one of
the above, another amino acid from the same class was used. At
positions 18 and 20 only four substitutions were made.
In these experiments, dilutions of the various substituted
analogs were incubated with "fixed" (see materials and methods)
APC for 6 hours. Subsequently, a set concentration of an unrelated
Ek-restricted peptide derived from hen egg lysozyme (HEL residues
1-14) was added along with T cells specific for this peptide. The
concentration of the second peptide was chosen so as to produce 75%
maximal stimulation of the HEL 1-14-specific hybridoma in the
absence of competitor peptides. If in the first step a given peptide
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was able to bind to Ek, this would be reflected by a decreased
amount of free Ek available to bind HEL 1-14, and therefore a
decreased stimulation of the HEL 1-14-specific T cell. The results
are expressed in Table 1.1 in terms of the relative capacity of a
given analog to achieve the same inhibitory effect as P12-26.
Smaller decimal fractions therefore correspond to peptides that
bind less well to Ek. As can be seen, these experiments implicate
primarily two residues, numbers 18 and 26, in MHC binding. Peptides
containing substitutions at position 18, for example, are .02 - .006
times as effective as P12-26 as competitors for binding of HEL 1-
14. Similarly, substitutions at position 26 reduced the
effectiveness of the peptides from .15 times that of P12-26 for a
conservative arginine substitution to .004 times that of P12-26 for
alanine and tyrosine substitutions.
At least one other substitution at nearly every other position
also affected the effectivenes of the P12-26 analogs as inhibitors
of binding to Ek . In particular, some substitutions at positions 19,
21, and 23 had effects on the order of 10- to 20-fold. These effects
however were at least 10-fold less severe than the effects of
substitutions at positions 18 and 26. Furthermore, while even quite
conservative substitutions (leu to ala at position 18, lys to arg at
position 26) decreased the effectiveness of the analogs as inhibitors
by roughly 10-fold or more, conservative changes at positions 19,
21, and 23 had little effect. These results suggest that while
several residues within 12-26 can affect binding to Ek , positions 18
and 26 play the most important roles.
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T cells have occasionally been seen to cross-react with other
peptides of the same MHC restriction. To control for the possibility
that the lack of competition seen for some peptides was not due to a
cross-reactivity of IG6.4 for certain P12-26 analogs, some of the
experiments were repeated using a T hybridoma specific for a
different Ek-restricted hybridoma. In this case the cell 2H6.41,
specific for HEL residues 105-120 was used. The results of these
experiments are also included in Table 1.1. As can be seen, there is
a close correlation with the results obtained with cell IG6.4. The
experiments also implicate primarily residues 18 and 26 in binding
to Ek. In fact, in this case, none of the peptides containing
substitutions at these positions except that containing a
conservative argine substitution at position 26 are capable of
achieving half-maximal inhibition of stimulation of 2H6.41.
The results of these experiments are summarized in schematic
form in Figure 1.1. In this figure the principle MHC contacts are
indicated by filled triangles. Residues which do not play a critical
role, but still appear to affect binding are indicated by open
triangles.
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Discussion
An alignment of several other Ek-binding peptides can be made
to 12-26 based on sequence homologies (Figure 1.2). In this
alignment, all except HEL 1-14, a weakly binding peptide (Guery, et
al., 1992), contain lysine at the position corresponding to 26.
Furthermore, all except HEL 1-14 and HEL 102-116, contain either
ala, leu or ile at the residue corresponding to position 18 in 12-26.
Thus our competition binding data and sequence homologies to other
good Ek-binders agree well with a simple Ek-binding motif
encompassing a basic residue preceded 8 residues before by a
hydrophobic amino acid.
The most significant exception to this rule would be HEL 102-
116. Adorini and co-workers have investigated the binding behavior
of this peptide, and proposed the following motif for Ek-binding:
Two hydrophobic (A, V, I, L) short chain, (such as S or T), or aromatic
(Y, W, F) residues six to eight positions before a basic residue, (K, R,
H). This model was based on the observation that binding was
affected to a certain extent by substitutions of the trp at the
position correponding to leu-18 in 12-26. Nevertheless, the binding
capacity of this peptide was more strongly dependent on the valine
C-terminal to it (Leighton, et al., 1991). Thus in a more refined
model, based on our data and the sequence homologies shown in
Figure 1.2, the aromatic residue may not play an important role. The
most important residues in the motif are simply the basic residue,
which by sequence comparison and effectiveness in our competition
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experiments is almost always a lysine, and the hydrophobic residue
which may variably be located either 7 or 8 residues away from the
basic residue.
Such a model would permit several unifying and simplifying
principles. First, this refined motif would explain the Ek-binding of
two peptides studied by Adorini and co-workers which did not
contain their proposed motif (Leighton et al., 1991). These two
peptides were entirely non-natural sequences containing alternating
hydrophobic and charged residues. They would fit a simple motif of
a basic residue preceded 8 residues before by a hydrophobic residue,
and they were found to be among the best Ek-binders of the peptides
studied.
Second, it would imply that binding of a peptide to a specific
class II molecule is primarily dependent upon two critical residues
in the sequence. Thus, binding to Ek would be more similar than is
presently proposed to binding to class I, where identification of
motifs based on sequence analysis of peptides eluted from class I
molecules has generally identified only two key residues as being
necessary (Falk et al., 1991).
For such a model to be valid, it would imply that the two
critical residues for MHC binding could be situated a variable
distance apart. A similar conclusion has recently been reached for
class I MHC proteins as the result of crystallographic studies (Guo,
etl: al., 1992). This work has shown that different peptides binding
the same MHC molecule are tightly bound at the anchoring residues,
but that different numbers of intervening residues can be
accommodated.
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As a final point, it is remarkable that we identified few
substitutions which seem to increase binding, considering the fact
that substitutions at many positions can significantly decrease
binding to Ek. This may simply be a reflection of the fact that 12-26
has essentially already been selected as having a relatively high
affinity for Ek, because it has been identified as the dominant
epitope of cl. This means it has a certain minimal affinity as well
as a relative affinity that is greater than that of other epitopes in
the protein. This and the fact that it matches quite closely the
other known Ek epitopes may indicate that its affinity for Ek is
already near a maximum.
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Table 1.1 Relative binding of 12-26 analogs to Ek
Position
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
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GI * *.. . . ....
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Hel 1-14
.75
.60
1.3
.005
1.0
.01
.004
.13
.15
.17
.13
.08
4.0
7.5
1.0
.60
.24
.75
.60
.60
.02
.004
.006
.01
.13
.06
.05
.55
.04
.12
.30
.11
.46
1.5
.05
.29
.08
.05
1.2
.38
2.0
1.1
1.7
.15
.30
.03
.02
.08
.60
.05
.34
.23
21
.75
.05
4.0
2.4
.43
.004
.007
.02
.15
.004
HEL 105-120
Nr
NT
NT
Nr
NTr
NT
NT
NT
Nr
Nr
NT
NT
NT
Nr
Nr
NT
NT
NT
NT
NT
.22
.14
2.2
.65
.40
.88
.47
1.9
2.5
.75
.08
.09
1.7
1.1
1.5
.66
1.4
.05
.15
.04
.08
.02
.9
.34
.25
.85
.9
.05
3.0
2.3
1.1
.09
Relative effectiveness of 12-26 analogs as inhibitors for binding to Ek. Values shown are the inverse of the relative
concentrations required to to achieve half-maximal inhibition of presentation of two other Ek-restricted peptides, HEL 1-14, and
HEL 105-120. The relative efficiency of unsubstituted 12-26 was defined as 1. Results shown are averages of duplicates. Dashes
indicate that half-maximal inhibition of presentation could not be achieved at the highest concentrations tested.
D14-A
E
L
K
Y
A15-S
D
L
K
Y
R16-A
D
L
K
Y
R17-A
D
L
K
Y
L18-A
D
K
F
K19-A
D
L
R
Y
A20oS
V
K
F
121-A
D
L
K
F
Y22-A
D
L
K
F
E23-A
0
L
K
Y
K24-A
D
L
R
Y
K25-A
D
L
R
Y
K26-A
D
L
R
Y
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Chapter 2
Abstract
The means by which the T cell receptor recognizes peptide-MHC
complexes is a subject of intense ongoing study. Models have been
proposed which postulate that V gene-encoded domains of the TCR
are primarily responsible for recognition of the MHC molecule,
whereas features of the peptide ligand are recognized by residues
lying at the respective V-J and V-D-J junctions of the a- and -
chains. Support for this model comes in part from previous studies
which have demonstrated that the presence of conserved sequences
in the junctional regions of TCRs from 12-26-specific T cells
corresponds to particular fine-specificities. In order to
characterize all residues having important interactions with the
TCR and to identify which parts of TCR are responsible for their
recognition, we determined the responsiveness of a large panel of
12-26-specific T cells to a set of 63 analogs of P12-26 containing
single substitutions. We find that the cells fall into two groups
having distinct fine-specificities at each position. For one group,
position 22 is the most important, in the sense that cells are most
stringent with respect to substitutions at this position. Comparison
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of these results with those obtained for T cells specific for the
peptide MCC 93-103, indicates that equivalent residues in different
_-k-restricted peptides have a similar importance in their respective
interactions with the TCR. Thus, the positioning of a given epitopic
residue within the MHC groove appears more important than the
nature of the amino acid, i.e. polar, hydrophobic, etc. as a
determinant of its interaction with the TCR. A second set of cells
having dramatically different fine-specificities has also been found.
These T cells also differ collectively in requiring a longer minimal
peptide. Strikingly, members of each group of cells have been found
to use the identical a-chain including Va and J genes and non-
germline encoded N region insertions. Thus, in this case, the same
a-chain is capable of combining with different P-chains to give
recognition of the same peptide-MHC complex, but with almost
entirely different fine-specificities. The conserved a-chain may be
involved in recognition of position 22 of 12-26, because the cells
have similar fine-specificities at this position. Taken as groups,
the switch between one type of fine specificity and the other
appears attributable to the use of different -chain junctions and
different J elements, because both use predominantly Va2 and V1.
We also present evidence to suggest that the aligment of TCRs
specific for different peptide-Ek complexes with these complexes
may be largely similar.
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I ntroduction
Knowledge of the means by which the TCR interacts with the
peptide-MHC complex is of profound importance for the
understanding of the immune system's ability to distinguish self
from non-self. Three similar models have been proposed to describe
the interaction of the peptide-MHC complex with the TCR (Chothia et
al., 1988; Claverie et al., 1989; Davis & Bjorkman, 1988). Based on
sequence homologies between the TCR and immunoglobulins, all
three postulate that the TCR recognizes antigen similarly to the Fab
domain of an antibody. Like the immunoglobulins, TCRs are encoded
by interchangeable V, D and J genes which are fused together to
create complete a- and P-chains. Again, in both Igs and TCRs the V
regions contain two Complementarity Determining Regions (CDRs)
that have been shown for Igs to be the principal points of contact for
antigen. A third CDR lies at the junctions of the V and J segments
(for a) and V, D and J segments (for A). The most striking difference
between the TCR and Igs is that while much of the diversity between
immunoglobulins comes from the use of a large number of different
V genes and thus lies in the first two CDRs, a far greater portion of
the diversity in TCRs occurs in CDR3. In the predicted structure of
the TCR, this third CDR would lie between the other two. These
observations led all three groups to propose that the first two CDRs
interact principally with the relatively non-diverse MHC molecules,
while the greater diversity of the third CDR could be exploited for
recognition of the many different antigens that would bind in the
cleft.
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Such a structure would explain several additional
observations. First, the maturation of MHC-restricted T cells in the
thymus requires the specific interaction of the TCR with MHC in the
absence of peptide antigen (Kisielow et al., 1988) and leads to
selection of T cells bearing certain Vs with inherent affinity for
the endogenous MHC molecule (Blackman, et al., 1989) in combination
with a variety of D and J segments. This shows that significant
interactions occur between the first two CDRs of the TCR V regions
and the polymorphic domains of the MHC molecules. No particular
association has been noted between expression of a given MHC
molecule and thymic selection of particular D or J segments. More
recently, residues involved in MHC recognition have been mapped to
CDR1 and CDR2 in mature T cells (Hong et al., 1992)
Such a structure would also explain the complementary
geometries of the MHC and TCR molecules. The width of the binding
site in MHC class I molecules is approximately 10A (Bjorkman et
al., 1987a). This would correspond quite closely with the distance
between CDRs 1 and 2 in the TCR structure. CDR3 would extend over
approximately 15A permitting it to interact with 5-6 residues of a
peptide bound in extended conformation.
Although it remains possible that there is no precisely fixed
physical interaction between the T cell receptor and the MHC
molecule, evidence is accumulating that the TCR does not have the
same sort of flexibility for diverse interactions as antibodies have
with protein antigens. For example, the same class I molecules are
simultaneously recognized by the TCR and the co-receptor CD8
(Connolly, et al., 1990; Ingold, et al., 1991; Salter, et al., 1990),
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which has a precisely defined binding site on the class I molecule.
This suggests that the TCR may be largely constrained in its
configuration of interaction with MHC.
Recently, Davis and co-workers have produced even stronger
evidence for the interaction of CDR3 with bound peptide using mice
transgenic for either the a- or f3-chains from a TCR specific for
moth cytochrome C residues 93-103 (Jorgenson et al., 1992) (MCC).
The T cell receptor in these mice is formed from a combination of
the protein coded for by the transgene and an endogenous
counterpart. If the mice are immunized with MCC, they produce T
cells bearing TCRs closely related to the orginal. If the mice are
immunized with peptides containing single substitutions at
particular positions, responding T cells use TCRs containing
compensatory changes in the junctional residues. Specifically, TCR
a-chains from -chain transgenics immunized with wild-type MCC
containing a lysine at position 99 all contained either aspartate or
glutamate in their a-chain junctions. T cells from the same mice
immunized with an aspartate at position 99 had lysine in the a-
chain junction. Substitutions in MCC at position 102 led to similar
compensatory changes in the -chain junctions of responding T cells.
It is important to determine whether the correlations one
observes between junctional sequences and antigen recognition are
the general rule or represent a specific case. One report has shown
a strong correlation between the recognition of the same peptide
antigen (tetanus toxin) and the use of a particular V gene, but no
conservation in the junctional regions (Boitel, et al., 1992). In
different systems it has been demonstrated that T cells recognizing
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a given peptide-MHC complex use a limited set of TCR a/ chain
combinations (Acha-Orbea, et al., 1988; Danska et al., 1990; Fink, et
al., 1986; Gold, et al., 1991; Lai et al., 1988). It is important to
know whether these V regions are involved only in MHC binding, or
whether certain ones are needed as frameworks to permit the
junctional regions to interact with a given peptide. One would also
like to know if the V regions themselves make important positive or
negative contacts with bound antigen. If particular domains of the
TCR can be shown to interact with the peptide or MHC, one would
like to know whether binding is in only one register, or whether it
can occur at different ends of the MHC molecule depending upon
which TCR genes are used.
Previous studies of I-Ek-restricted, 12-26 specific
hybridomas have shown that over 90% use one of two closely related
members of the Vp2 family, and 70% use V1pl (Lai et al., 1988).
Furthermore, close correlations have been identified between
sequences in both the a- and -chain junctions and reactivity to
peptides containing substitutions at position 22. In a second study,
among eight a-chain sequences determined, six contained identical
a-chain junctions (Lai et al., 1990). A seventh differed from the
other six only in that its a-chain junction contained a single amino
acid deletion. This cell was the only one in the panel incapable of
responding to P12-26 containing a tyrosine to phenylalanine
substitution at position 22 (P12-26(22F)). This observation,
therefore, implicated the a-chain in recognition of position 22.
Interestingly, if an alignment is made between 12-26 and MCC 93-
103 (see Figure 1.2) position 22 of 12-26 would correspond to
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position 99 of MCC 93-103. As noted above, substitutions at this
position induce compensatory changes in the a-chain junctions of T
cells in -chain trangenic mice. This parallel suggests that the
same region of the T cell receptor might be used for recognition of
equivalent residues in different Ek-restricted peptides. Since these
T cells use different Va and V13 genes, this also suggests that
different TCRs specific for Ek would align with the MHC molecule in
a similar way, and that the most critical residues for recognition
might be selected by their positioning in the MHC groove.
However, correlations were also made between fine-
specificity at position 22 and sequences in the -chain. It was
observed that among the cells containing the identical a-chain
junctions, all but one did not accept a tyrosine to histidine
substitution at position 22. This T cell's -chain differed primarily
from all the others in that it lacked a conserved non-germline-
encoded glutamate in its junction. Thus, there does not appear do be
an absolute division whereby fine-specificity at position 22 would
be determined entirely by either the a- or 13-chains. It is possible,
however, that this is merely an indirect consequence of differences
in a part of the TCR whose principal function is recognition of
another residue of the peptide.
To expand upon these studies we were interested to see how
many different residues in the peptide seemed to affect fine-
specificity. It was desirable to further examine the observed
correlations between fine-specificity at position 22 and sequences
in the a- and 13-chains using a larger panel of T cells, and search for
correlations at other positions. We were also interested in
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determining whether only the junctional regions of the TCR were
implicated in recognition of these residues, or whether other parts
of the TCR were as well. More specifically, we were interested in
pursuing possible parallels between the 12-26 system, and the other
Ek system, MCC. Davis and colleagues have shown that when charged
residues are substituted at positions 99 and 103 in MCC, T cells that
recognize these peptides often contain complementary charged
residues in their junctions. We were interested to see whether the
equivalent residues of 12-26 were of equal importance, and whether
a similar means of recognition was employed. If this is indeed the
case we would expect to identify position 25 as a critical T cell
contact, and, further, might expect to find correlations between the
recognition of substitutions at this position and particular
sequences in the P-chain junction.
In this chapter we describe the characterization of a large
panel of 12-26-specific hybridomas using a set of 63 analogs of
P12-26 containing single substitutions. Comparison of the results
to those obtained elsewhere indicates that the importance of the
interaction of equivalent residues in different Ek-restricted
peptides with the TCR is determined by their position within the
MHC groove. Additionally, by comparing the sequences of the TCRs of
several of the T cells, we are able to ascribe changes in the fine-
specificities to particular differences in TCR sequence.
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Results
T cells specific for 12-26 were made from CBA mice after a
primary response induced either by immunization with cl protein or
P12-26 peptide. Fusions were performed between the T cell
receptor deficient thymoma BW5147a-1- (White et al., 1989) and
lymph node cells from three different mice. In an initial screening,
45 hybridomas from P12-26-immunized mice and 27 hybridomas
from cl-immunized mice were tested against P12-26 and the
truncated peptide PP15-26 and their MHC restrictions determined.
As had previously been observed in a study of 12-26-specific
hybridomas (Lai et al., 1987), all those produced in k-haplotype mice
by immunization with cl responded equally well to PP15-26 as to
P12-26 and were Ek-restricted Table 2.1. Notably, however, in these
experiments hybridomas produced by immunization with 12-26 fell
into two distinct categories, those which responded equally well to
P12-26 and PP15-26, and those which responded to P12-26, but did
not respond at all to concentrations of PP15-26 as high as 50pzg/ml.
Several of the hybridomas which proliferated stably in culture
were selected for further characterization. In the study of 12-26-
specific hybridomas mentioned above, Ad-restricted hybridomas
from Balb/c mice could be subdivided into two categories based on
their minimal peptide requirement, those which respond better to
the peptide PP15-26 than to the peptide P12-24, and those with the
opposite preference for peptide. We therefore tested all cells
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against P12-24. Unlike in Ad, no cell was able to respond to
concentrations of 12-24 as high as 100g1g/ml (not shown). It was
observed, however, that the P15-26-responders had a sensitivity for
12-26 which is significantly higher on average than for the non-
responders. The average concentration of 12-26 necessary for half
maximal stimulation among the responders shown in Table 2.2 is
0.27.M. P15-26-non-responders, by contrast, require an average
concentration of 1.41M.
Because of the difference in the types of hybridomas produced
by immunization with P12-26 or by cl protein, we considered the
possibility that processing of the protein is at the origin of the
exclusive production of hybridomas which respond to P15-26 in cl-
immunized mice. Such a situation might arise, for example, if the
exact peptide produced by processing of cl were capable of
stimulating only a limited subset of T cells which can respond to the
peptide P12-26 which does not require processing in order to be
presented. To test this hypothesis, we examined the responsiveness
to cl protein of the different sets of hybridomas which responded
either only to P12-26, or to both P12-26 and P15-26. Figure 2.1
shows the results of such an experiment. A representative P15-26-
responder (1.9) can be stimulated by cl protein, although, as has been
previously observed (Lai et al., 1987), about 10-fold more protein
than peptide on a molar basis is required. By contrast, two of the
P15-26-non-responders, 1.21, and 2.4, are not stimulated by the
protein, and the third, 2.19, requires significantly more protein on a
molar basis. This is not simply a consequence of a difference in
sensitivity, because the hybridomas shown have approximately the
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same sensitivities to peptide. A similar observation has been made
for an Ed-restricted hybridoma (26.1.E) that differs from other Ed-
restricted hybridomas studied to date in that it too does not respond
to P15-26 or to cl protein (not shown). This hybridoma was also
produced by immunization with P12-26 peptide. These results
suggest that processing of cl protein produces a peptide to which
only a limited set of Ek-restricted T cells can respond.
Furthermore, this effect is probably at least partially responsible
for the fact that the 12-26-specific T cells previously described
from k-haplotype mice are more homogenous than those in d-
haplotype mice (Lai et al., 1987). Because of this additional
diversity in fine-specificities, the experiments described below
were conducted using T cells derived from mice immunized with
P12-26.
We then tested some of these T cells for their responsiveness
to the various substituted analogs described in chapter 1. A total of
23 different 12-26-specific Ek-restricted hybridomas, including
three which had been previously isolated and partially characterized
(Lai et al., 1987; Lai et al., 1988) were tested. Although initial
examination of the results revealed no clear pattern of
responsiveness when the cells were considered as an ensemble, it
was observed that if P15-26-responders and non-responders were
grouped separately, patterns did emerge. The results are presented
in Figure 2.2 grouped in this way. In order to facilitate the
presentation of the data for all of the hybridomas in one figure, the
following format has been used. The substitutions made in the
peptides are indicated in the left-hand column. The names of the
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various T cells tested are in the top row. Each rectangle in the
figure corresponds to the response of a given T cell to a peptide, and
the sensitivity of a given T cell to a given peptide is indicated by
the darkness of the rectangle. The two groups of cells show clear
differences in their stringencies with respect to substitutions at
each position. For example, T cells on the left-hand side of the
panel (cells which respond to P15-26) in general accept a variety of
different substitutions at positions 16 and 17. By contrast, with
two minor exceptions (cells 1.11 and 81), they all accept either no
substitutions at all, or only phenylalanine in place of the wild-type
tyrosine at position 22. T cells on the right-hand side of the panel
(P15-26-non-responders), by contrast, in general readily accept
substitutions at position 22, but do not at positions 16 and 17.
Within each group there are distinct preferences for certain
substitutions at several positions. For example, P15-26-non-
responders all accept only serine as a substitution at position 20.
P15-26-responders, however, taken together, have no preferred
substitution at this position. At position 21, P15-26-responders
again show a preference for hydrophobic side chains, in this case
alanine and leucine. P15-26-non-responders, in general do not
accept substitutions at this position. As mentioned above, P15-26-
responders accept only aromatic amino acids at position 22, while
P15-26-non-responders accept a variety of substitutions, but show
a clear preference for aspartate. At position 25, P15-26-responders
show a preference for hydrophobic residues, alanine and leucine,
while P15-26-non-responders prefer the basic arginine. Finally, at
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position 26, P15-26-responders cells prefer arginine, while in this
case P15-26-non-responders prefer leucine.
These results show that different residues in 12-26 play roles
of variable importance for the recognition of the epitope by the TCR.
For P15-26-responders, position 22 appears to be the most
important, in that T cells are the most stringent with respect to
substitutions here, although other positions are restrictive with
respect to substitutions as well. An key question is whether the
importance of a given residue is determined by its localization
within the MHC groove, or by the particular amino acid at the
position, i.e. polar, hydrophobic, etc. One means of determining this
is to compare different peptides having the same MHC restriction to
see if the equivalent residues appear to play the same role for
recognition by the TCR. Figure 2.3 shows such a comparison between
the results obtained here for P15-26-responders and those reported
for another Ek-restricted peptide, MCC (Fox, et al., 1987). The
peptide alignment is the same as that shown in Figure 1.2. Although
not all positions were tested for the MCC peptide, where the
comparison can be made, the equivalent positions do appear to play
the same role. Position 99 in MCC, the equivalent of position 22 in
12-26 is the most stringent with respect to substitutions. This
cannot be the result of the particular class of amino acid at this
position because in MCC, position 99 is a lysine, and in 12-26
position 22 it is a tyrosine. Similarly, positions 98 in MCC and 21 in
12-26 are both spacer residues, apparently making no important
contacts with the TCR (or MHC). MCC positions 101 and 102 also
appear to have similar roles to positions 24 and 25 of 12-26,
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despite the difference in the amino acids found at these positions.
These results, therefore, suggest that the importance of a given
residue for its interaction with the TCR depends upon its
localization in the MHC groove.
Possible binding of 12-26 to Ek in alternative conformations
The results obtained for P15-26-non-responders are more
difficult to interpret. For these cells, the pattern of fine-
specificities appears different at virtually every position from that
obtained for P15-26-responders. To explain this contrast, we
considered the possibility that 12-26 might bind to Ek in more than
one conformation. The justification for such a hypothesis is based
on the following reasoning: MHC binding is a necessary but not
sufficient condition for stimulation of all T cells. Therefore, if a
given substitution prevents the binding of the peptide to MHC, all of
the T cells in the panel should no longer respond. Furthermore, at
every position that contacts MHC there should be a certain hierarchy
of preferred substitutions. For example, if a hydrophobic residue is
important for MHC binding at a certain position, leucine and alanine
substitutions may not affect binding at all, tyrosine may work less
well, and lysine and aspartate may both work poorly. In contrast,
the interaction of the TCR with the same peptide-MHC complex may
be different for each T cell. Thus, for those positions that do not
interact with MHC, some will be TCR contacts for a given T cell and
not for others. Furthermore, even for two TCRs that contact the
same residue, the nature of their interactions with it will not
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necessarily be the same. That is, in one case the interaction may be
based on a charge pair, while in another it may be a hydrogen bond.
Thus, the hierarchy of acceptable substitutions at a given position is
expected to be different between T cells for residues whose
predominant interaction is with the TCR.
To see if these differences in the roles of various residues
were indeed reflected in the responsiveness of T cells, we compared
the results obtained in the competition binding experiments
described in the preceding chapter to the fine-specificities of the T
cells we have studied. As can be observed in Figure 2.4, the
correlation is indeed quite high for P15-26-responders. The two
residues identified as being most important for MHC binding, 18 and
26 give fairly uniform patterns of responsiveness for all of the
cells. Furthermore, there is a direct correlation between the extent
to which a given substitution affects binding to MHC in the
competition assay, and the extent to which the T cells in this group
respond. At position 18 no cell responds to the substitution, an
aspartate, which reduces binding most in the competition assay. At
position 26 the single substitution which can generally be tolerated
by all T cells is an arginine. Again, this conservative change has the
most minor effect on binding in the competition assay.
In contrast to the P15-26-responders, the P15-26-non-
responders have a pattern of reactivity to the peptides that is
seemingly unrelated to their MHC-binding capacities. In fact at
several different positions, strong preferences can be observed
among all hybridomas for one amino acid substitution over others,
but the particular preferred substitutions do not correlate with the
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ability of the peptides to bind in the competition assays. At
position 20, all of the cells accept only an alanine to serine change,
whereas this peptide seems to bind MHC only slightly less well than
the wild-type and equivalently to others substituted at the same
position. At position 22, although a variety of substitutions are
accepted by various T cells, a strong preference for an aspartate is
observed. The peptide containing this substitution binds worst to Ek
among the five substituted at this position. Finally, at position 26,
a preference for a lysine to leucine change is observed. This is in
marked contrast to the P15-26-non-responders which prefer the
more closely related arginine and to the competition data suggesting
that this peptide should bind less well than the wild-type or the
arginine-substituted peptide.
The above data give several examples where a close
correlation is observed between the MHC-binding capacity of the
various peptides in the competition assay with their patterns of
stimulation of P15-26-responders, but not P15-26-non-responders.
Two possible explanations exist for this observation. The first and
more classical is that two distinct groups of T cells, each
containing conserved and distinctive features in their TCRs respond
to 12-26. The second is that 12-26 is capable of binding to Ek in
two distinct conformations, one of which induces P15-26-responder
cells, and the other of which stimulates P15-26-non-responder
cells. The strict distinction between the fine-specificities of the
cells and the difference in the minimal peptide requirements led us
to consider this second possibility.
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Two groups have, in fact, reported indirect evidence that
supports the idea that a single peptide could indeed bind MHC in more
than one conformation (Bhayani and Paterson, 1989; Kurata and
Berzofsky, 1990). Two different observations argue strongly
against it in this case, however. First, if 12-26 could indeed bind to
Ek in an alternative conformation, the critical residues should be
those identified by the fine-specifity tests of the P15-26 non-
responders. Thus, four residues should be essential, an ala or ser at
position 20, a tyr or asp at position 22, a basic residue at position
25 and a lys or leu at position 26. Such a motif bears no
resemblance to the pattern of critical residues identified in other
good Ek-binding peptides (Figure 1.2). While it is possible that two
quite disparate motifs exist for Ek binding, we would expect that
other epitopes containing sequences resembling this second motif
would have been identified, which is not the case.
An even stronger argument comes from analysis of the TCR
genes from the 12-26-specific hybridomas studied here. We have
determined the Va and Vp gene usage of many of the hybridomas
described above using PCR. All of six P15-26 non-responders and
four of six P15-26 responders whose fine-specificity has been
studied here employ the same combination of V31 with closely
related members of the V2 family (Table 2.3). This similarity in
the TCRs of the two groups of cells strongly suggests that they are
recognizing a similar peptide-MHC complex, and that the differences
in responsiveness of the two groups of cells represent the particular
structures within this complex that are chosen for recognition by
each group. T cells specific for other peptides also restricted by Ek
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use entirely different combinations of Va and V (Hedrick, et al.,
1988; Sorger, et al., 1990; Winoto, et al., 1986), indicating that this
is not just a reflection of the fact that P15-26 responders and non-
responders are restricted by the same MHC molecule.
Fine-specificity at position 22 correlates with usage of a conserved
TCR a-chain sequence
A previous study of 12-26-specific T cells had described
evidence linking recognition of position 22 alternatively to
sequences in either the a- and P-chain junctions (Lai et al., 1990).
However, in both cases the evidence was only indirect. As a means
of further examining whether one chain of the TCR in particular was
responsible for recognition of this position, and because all previous
analysis had used cells from the P15-26-responder group, we
determined the sequences of the TCRs from cells from the group of
P15-26-non-responders. Cell 1.13 was chosen as a representative
P15-26-non-responder, and cell 1.21 was also chosen because it
was one of only two in the group which accepted only aromatic
substitutions at position 22. Figure 2.5 shows the sequence of the
a-chain for these cells, as well as the sequence of the 13-chain for
cell 1.21. The 13-chain sequence for 1.13 has not yet been
determined. Confirming the PCR analysis, the -chain of 1.21 uses
Vp1 along with a member of the Jpl family. This result is
significant in that most previously characterized Ek-restricted T
cells specific for 12-26 (all P15-26 responders) also used Vpl1, but
all used Jp2.
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The two T cells employ closely related members of the Va2
family, as well as relatively closely related Ja elements (Figure
2.6). Strikingly, we observed that the sequence of the a-chain of
1.21 is identical to the a-chain of a previously studied P15-26-
responder T cell, 41 (Lai et al., 1988). Several aspects of this
observation are worthy of note. First, 41 uses Vp14 and a member of
the Jp2 family paired with the a-chain described above, while 1.21
uses Vpl with J1.6. This is not the first time that identical a-
chains have been found to pair with different 5-chains. Notably, cell
31 was found to share the identical a-chain with several other 12-
26-specific T cells (Lai et al., 1990). However, for these cells, very
closely related -chains were used. Additionally, (Jorgenson et al.,
1992) found that a variety of significantly different -chains were
able to pair with the identical a-chain to effectuate recognition of
substituted MCC peptides. However, in their experiments the cells
were derived from mice transgenic for this a-chain, and the cells
were therefore constrained to using it. Our results therefore show
that a very high degree of selection exists for the use of this
particular a-chain, and that it apparently is capable of contributing
to the recognition of 12-26 in concert with different -chains.
Second, the fact that the identical a-chain is used by both
cells along with related Vs lends support to the idea that P15-26-
responders and non-responders do not recognize 12-26 bound to Ek in
different conformations. It has previously been shown that when T
cells recognize different determinants, even within the same
peptide they employ different V and V genes (Nanda, et al., 1992).
Even relatively small changes in the fine-specificity of T cells are
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often accompanied by changes in the V genes used (Jorgenson et al.,
1992). Thus, it is difficult to imagine that these two T cells, 41 and
1.21 could be recognizing 12-26 bound to Ek in different
conformations if they employ such closely related TCR genes.
Third, since these cells employ identical a-chains and the
same Vp, this observation reinforces support for the hypothesis
described above that differences in the 13-chain junctions or Jp usage
are at the origin of the gross differences in fine specificity between
P15-26-responders and non-responders.
Finally, it is significant that 1.21 is one of only two P15-26-
non-responders that have the typical fine-specificity at position 22
of P15-26-responders. This suggests that the conserved a-chain
used by 41 and 1.21 might be primarily responsible for recognition of
this residue. Such a conclusion would be dependent on 41 also having
a similar fine-specificity at position 22. Previously, 41 was tested
only against two analogs of 12-26 containing aromatic substitutions
(Lai et al., 1988). We therefore verified that 41 responded to other
substitutions at position 22 in a similar way as 1.21. Figure 2.6
shows that this is indeed the case. As is the case for 1.21 and most
P15-26 responder cells 41 accepts no other substitution at position
22 up to concentrations 1000-fold higher than that required for
stimulation by 12-26. These data, therefore, suggest that the
conserved a-chain employed by 41 and 1.21 determines the fine-
specificity of these T cells at position 22.
As mentioned above, data has been presented linking the fine-
specificity of one group of T cells at position 22 to sequences in
both the a- and -chains of the TCR (Lai et al., 1990). For the 3-
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chain, this consisted of the observation that 6 out of 7 cells having
identical a-chain junctions had identical fine-specifities at
position 22 and all contained a glutamate residue at position 100 in
their -chain junctions. The seventh cell sharing the same a-chain
junction (cell 51V), lacked the glutamate in its -chain junction, and
was the only one among the 7 which accepted a histidine
substitution at position 22 (Figure 2.7). Evidence implicating the
a-chain consisted of the identification of a partially overlapping set
of 6 cells containing identical a-chain junctions which all accepted
only a phenylalanine substitution at position 22. A seventh cell
(241) differed from the others in that it contained a single deletion
in its a-chain junction, and that it was the only one in the group
which did not accept a phenylalanine substitution at position 22.
These data are reproduced in Figure 2.8.
These correlations between the fine specificity at position 22
and sequences in both the a- and 3-chains could be the consequence
of interactions with structures in the TCR selected for recognition
of this residue, or of indirect consequences of modifications in
structures that are principally involved in recognition of others. To
determine whether the only correlation between the conserved
glutamate in the -chain junction was with fine-specificity at
position 22, we examined the response of cell 51V to peptides
substituted at other positions, and compared the results to those
obtained for cell 31. The most significant difference observed was
that whereas 31 accepts only alanine and leucine substitutions at
position 25, 51V also accepts arginine and tyrosine (Figure 2.9). In
fact, 51V responds to P12-26(R25) approximately 4-fold better than
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the peptide containing the original lysine at this position. Thus, as
there is no response of 31 to concentrations of P12-26(R25) as much
as 1000-fold greater than those required for stimulation by P12-26,
there is at least a 4000-fold difference in the relative sensitivity
of 51V and 31 to this substituted peptide, and at least a 1000-fold
difference in relative sensitivity to P12-26(Y25). The effect on
fine-specificity at this position may be therefore be greater than at
position 22. This suggests that the conserved glutamate residue in
the -chain junctions of 31 may have been selected for recognition
of other residues (perhaps residue 25), and that the different fine-
specificities of 51V and 31 at position 22 may be an indirect
consequence of this.
The two cells sharing the identical -chain and differing by a
single amino acid deletion in their a-chains, 241 and 711, have also
been compared for their acceptance of substitutions at positions
other than 22 (Ming-Zong Lai, personal communication) In contrast
to the results obtained for cells 31 and 51V, no other differences in
fine specificity have been found for these cells. Taking the
ensemble of these results into consideration, therefore, it appears
that conserved sequences in the a-chain junction are primarily
involved in recognition of position 22 of 12-26, while variations in
the 13-chain junction may affect fine-specificity at this position
only indirectly.
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Discussion
We have characterized the set of Ek-restricted T cells specific
for the immunodominant epitope of cl. Although previous studies
had found that all cells specific for 12-26 could also respond to the
truncated peptide P15-26, we identified a second set of cells
produced only upon immunization with P12-26 which required a
minimal peptide which was longer. The explanation for this
difference appears to be that processing of cl protein produces a
peptide which is capable of only inefficiently stimulating this
second set of cells (referred to as P15-26-non-responders), because
P15-26-non-responders appear to respond to cl protein significantly
less well than P15-26-responders.
The fine-specificities of these two sets of cells are
dramatically different. While P15-26-responders are extremely
stringent with respect to substitutions at position 22, this is the
position of lowest stringency for non-responders. At several
positions the groups differed collectively in which amino acid
substitutions were preferred. We reasoned that it should be
possible to confirm the identification of MHC contact residues by
examination of fine-specificity data. Substitutions at positions
which contact MHC should, in principle, have a similar effect on
stimulation of all cells which recognize the same peptide-MHC
complex. A comparison of these results to the competition binding
experiments described in the previous chapter revealed a close
correlation between the probable MHC-contact residues predicted by
the two methods, but only for the P15-26-responders.
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This difference and the fact that a different minimal peptide
was required led us to consider the possibility that P15-26-non-
responders recognized P12-26 bound to Ek in an alternative
conformation. Such a hypothesis is supported by two reports which
have described T cells which appear to recognize the same peptide
bound to the same MHC molecule in different conformations (Bhayani
& Paterson, 1989; Kurata & Berzofsky, 1990). The most convincing
evidence that this is not the case, however, is that almost all cells
from both the responder and non-responder groups use the same Va2
and V1pl genes. Since T cells specific for other peptides bound to Ek
employ different TCR genes (Hedrick et al., 1988; Sorger et al.,
1990; Winoto et al., 1986), this coincidence would be difficult to
explain if P12-26 were binding in two entirely different
conformations. Furthermore, two hybridomas have been identified,
one of them (41) a P15-26-responder, and one (1.21) a P15-26-non-
responder, which use identical a-chains. Again, this result is best
explained by the groups of cells recognizing the same complex.
If the peptide-MHC complex recognized by P15-26-responders
and non-responders is assumed to be the same, an important
difference appears to exist between the two groups of cells in the
number of peptide residues contacted by the TCR. Among the P15-
26-responders we find that residues 16 and 17 can generally be
freely substituted, while the two more N-terminal residues, 14 and
15, tend either to accept many substitutions, or none at all. Since
residue 14 is not necessary for stimulation of these T cells, it can
be concluded that the principal residues necessary for stimulation
of these T cells lie between 18 and 26. The cells which do not
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respond to substitutions at positions 14 through 17 may not mainly
because these substitutions introduce negative interactions with
the TCR, as opposed to causing the loss of an essential contact. If
the probable MHC-contact residues 18 and 26 are excluded, the TCR
would be expected to make essential contacts with residues 19-25.
This is good agreement with the number of residues with which
CDR3 is predicted to interact, if the peptide assumes an extended
conformation (Claverie et al., 1989).
Surprisingly, both the fact that the minimal peptide for P15-
26-non-responders includes at least residue 14, and the fact that
these cells accept virtually no substitutions at positions 14 and 15
indicates that the TCRs of these cells make essential contacts with
these residues. Positions 24 and 25 also seem to be critical for
these cells. P15-26-non-responders, therefore, seem to interact
with residues which are much more widely dispersed in the peptide
than for P15-26-responders. T cells from these two groups employ
the same set of Va and Vp genes, which, if conventional models for
TCR structure are correct, suggests that their interaction with the
Ek molecule is similar. If this is the case, it would imply that the
CDR3 of P15-26-non-responders extends over a much longer surface,
and contacts many more residues than that of the responders. This
issue will require further investigation.
Previous studies of the fine-specificity of 12-26-
specific T cells have been limited to the use of peptides containing
aromatic substitutions at position 22. One of the goals of this work
was to identify other positions where correlations could potentially
be found between fine-specificity and TCR sequence. Interestingly,
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all cells tested to date that recognize a minimal peptide of P15-26
focus their response on residue 22, in the sense that this residue
appears to be the most restrictive with respect to substitutions.
This does not appear to be simply a minor consequence of
differences in the way individual T cells recognize the peptide-MHC
complex. Indeed, we would argue that the tyrosine at position 22 is
particularly favored for interaction with the TCR. Lai et al. (1990)
identified cells having three different types of fine-specificities
with respect to substitutions at position 22: Those that accepted no
aromatic substitutions, those that accepted only phenylalanine, and
those that accepted phenylalanine and histidine. We have shown here
that among the cells that accept no aromatic substitutions, some (81
and 1.11), do accept other substitutions to some degree. Thus,
despite the fact that position 22 appears to be the single most
important position interacting with the TCRs of cells of this group,
several different means appear to be used to effectuate recognition.
This suggests that the 12-26-Ek complex selects T cells bearing
TCRs focussing their interaction on this position.
The identification of the P15-26-non-responder cells for
which position 22 is the single position of lowest stringency with
respect to substitutions is somewhat difficult to understand in this
context. However, T cells of this group have a sensitivity for 12-26
which is on the average six-fold less than for P15-26-responders.
They are also much more stringent with respect to substitutions at
virtually every other position. Therefore, it may be that TCRs of the
highest affinity are those which interact with position 22. Those
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which cannot, must make up for this loss by relatively tenuous
interactions with other residues.
If position 22 is indeed the most critical residue for the
recognition of the 12-26 epitope, one may ask whether this is
because of the particular amino acid at this position, i.e. tyrosine, or
because this position interacts most strongly with the TCR because
of its localisation within the MHC groove. One way to answer this
question is to ask whether residues at the equivalent position in
other Ek-restricted peptides have a similar importance. One
previous study examined the response of two hybridomas specific
for MCC 93-103 to peptides substituted at positions 98, 99, 101,
102 and 103 (Fox et al., 1987). Indeed, in this study, residue 99,
which would be equivalent to residue 22 in 12-26 was found to be
the position most stringent with respect to substitutions. In MCC
93-103, the amino acid at this position is lysine, suggesting that it
is the localisation of the residue within the MHC groove, and not the
particular amino acid found at this position that is responsible.
Figure 2.3 shows a schematic representation of the results of this
study and compares them to the results we have obtained. Such an
alignment indicates that not only at position 22, but at all others
where comparisons can be made, the importance of the residue for
TCR recognition is similar. Position 98 in MCC 93-103 and position
21 in 12-26 both accept many substitutions, and are therefore
classified as spacer residues. Position 24 and 25 and their
equivalents in MCC 93-103 are of similar, although lesser,
importance than position 22 for TCR recognition. These
observations, therefore, strongly suggest that that the positioning
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of a given residue more than the particular amino acid class to
which it belongs determines the importance of its interaction with
the TCR.
If this is in fact the case, one can ask whether the interaction
of MCC 93-103-specific and 12-26-specific TCRs with their
respective antigens are similar. Using mice transgenic for either
the a- or 3-chain from an MCC 93-103-specific T cell, (Jorgenson et
al., 1992) showed that recognition of MCC position 99 seemed to be
predominantly the result of interactions with the a-chain. This led
them to propose a model with the TCR aligned across the peptide-
MHC complex such that CDR1 and 2 interacted with the MHC
molecule, while the junctional residues of the a-chain interacted
with the N-terminal end of the bound peptide and the junctional
residues of the 13-chain with the C-terminal end. Here we present
data indicating that despite the use of different TCR genes the
alignment of the TCR with Ek-peptide complexes may be similar. Lai
et al. (1990) originally identified 7 T cells bearing TCRs which
differed primarily in that one, 241, contained a single alanine
deletion in its a-chain junction. This cell was the only one in the
group incapable of recognizing P12-26(22F). This evidence,
therefore, implicated the a-chain in position-22 recognition.
However, correlations could also be made between position-22
recognition and the P-chain. Seven T cells were identified with
closely related -chains, all containing a conserved glutamate at
position 100 in their junctions, and all incapable of recognizing a
histidine substitution at position 22. An eighth, which lacked the
glutamate at position 100, did respond to the histidine-substituted
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peptide. Thus, for this group of 12-26-specific T cells, both chains
of the TCR appeared to affect recognition at position 22. By
examining the response of these T cells to a larger set of peptides,
we have found that while the deletion in the a-chain junction
appears to affect primarily fine-specificity at position 22, changes
in the -chain junction appear to affect recognition at other
positions (e.g. position 25) just as significantly. Therefore, for both
MCC 93-103-specific T cells and this set of 12-26-specific T cells,
recognition of equivalent residue may be by the a-chain.
A particularly striking discovery that also supports this
hypothesis was the finding that cell 1.21 employs the identical a-
chain to one used by a previously described T cell, 41 (Lai et al.,
1988). Lai et al. (1990) found one a-chain was found paired with
closely related 13-chains in 12-26-specific hybridomas, and Davis
and colleagues have found that transgenic a-chains can pair with a
variety of different -chains. However, to our knowledge, this is the
first example of an identical a-chain combining with widely
different -chains in a non-transgenic animal. This indicates,
therefore, that a very high degree of selection exists for the use of
this a-chain sequence, which suggests that it is responsible for
recognition of elements of structure in either the bound peptide, or
the Ek-molecule, or both. A likely contact residue for this a-chain
is the tyrosine at position 22. Cell 1.21 is one of only two P15-26-
non-responders which accept only a phenylalanine substitution at
position 22. Thus despite the differences in minimal peptide
requirement and fine-specificities at other positions for 1.21 and
41, the primary points of comparison of these two cells are a similar
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responsiveness to substitutions at position 22 and usage of the
identical a-chain. Cell 1.13, which like most of the other members
of the P15-26-non-responder group accepts preferentially an
aspartate at position 22 uses a different a-chain. These data,
therefore, support the view that three different a-chains, that of
cells 41 and 1.21, that of 31, 51V and others in this group described
by Lai et al. (1990), and that studied by Jorgenson et al. (1992), are
principally responsible for recognition of the amino acid occupying
the equivalent position in the MHC groove.
A final piece of evidence supporting this possibility was the
contrasting response of cells 51V and 31 to substitutions at position
25. These two cells differ primarily in that 51V contains a glycine
residue at position 100 in its 3-chain junction, whereas 31 contains
a glutamate that is conserved among several other 12-26-specific
cells. This difference was originally correlated with variations in
fine-specificity at position 22 (Lai et al., 1990), but the more
extensive analysis described here found that correlations could also
be found at other positions, in particular with position 25. Most
interestingly, 31 was found to be at least 4000-fold more selective
than 51V against 12-26 containing an arginine substitution at this
position in place of the normal lysine. This suggests that the
conserved glutamate residue at position 100 of the P-chain may be
involved in recognition of position 25 of 12-26, perhaps via a salt
bridge. (Jorgenson et al., 1992) found that when a-chain transgenic
mice were immunized with MCC 93-103, all resulting hybridomas
analysed contained asparagines at the same position 100 of their 3-
chain junctions. A similar result was previously obtained in non-
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transgenic mice by Hedrick and colleagues (1988). When the mice
were immunized with an MCC 93-103 analog containing a lysine
instead of the normal threonine at the residue equivalent to position
25 of 12-26 (MCC position 102), the responding T cells often
contained glutamates or aspartates in their -chain junctions. The
authors interpreted the results to indicate that these residues made
direct contacts with position 102 of MCC. These parallels suggest
the intriguing possibility that despite the usage of different Va and
Vp genes, TCRs specific for different peptides restricted by the
same MHC molecule may have a largely similar interaction with the
peptide-MHC complex.
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Figure 2.1 Reactivity of 15-26-responders and non-responders to cl
protein
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Comparison of the response of a representative 15-26-responder (cell
1.9) and three 15-26-non-responders to 12-26 peptide, (A) and cl
protein (B).
73Figure 2.2 Response of 12-26-spedfic T hybridomas to single-substituted analogs
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Figure 2.3 Equivalent residues in two Ek-restricted peptides play similar roles in their interaction with the TCR
NT NT A
LEU 12 GLU1 3 ASP1 4 ARG 15 ALA1 6 ARG17 LEU1 8 LYS1 9
A
ALA2 0
-AIE TYR Y Y
ILE21 TYR2 2 GLY23 LYS2 4
NT NT NT NT NT NT
GLN8 9 GLU9 0 ARG9 1 ALA9 2 ASP9 3 LEU94 ILE95V
NT NT -
ALA9 6 TYR9 7 LEU98
A NT A 
LYS9 9 ASN1 0oo0 ALA1 01THR 0 2 LYS 3
V
Comparison of the role of each residue in 12-26 in interacting with the TCR of 15-26-responder cells with the role of
the equivalent residues in another Ek-restricted peptide, MCC 93-103. Roles of each residue in 12-26 are based on the
results presented in Figure 2.2. The roles attributed to each residue in MCC 93-103 are based on the fine-specificity
analysis two T hybridomas by (Fox, et al, 1987), using the classification system of (Jorgensen, et al, 1992). Alignment
of the peptides is the same as in Figure 1.2. Probable MHC-contact residues are indicated by downward-pointing filled
triangles. Upward-pointing filled triangles indicate residue where responsiveness of T cells is affected by conservative
substitutions. Upward-pointing checked triangles indicated residues where responsiveness is affected by conservative
replacements, but some non-conservative replacements are accepted. Upward-pointing empty triangles indicate
residues where responsiveness is affected by non-conservative substitutions, and conservative changes have no effect.
A dash above a residue indicates that even non-conservative substitutions generally have little effect. NT, not tested.
LYS25 LYS2 6V
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Figure 2.4 Comparison of competition binding results to fine-specificity data
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Figure 2.5 Sequences of T cell receptor genes from 15-26-non-responders
C A A S
TGT GCA CCA AGT
Va2.3
P N T N K V V F G T G T R
CCC AAT ACC AAC AAA TG GTC TTT GGA ACA GGG ACT CGA
Ja27
1.21 (X
C A A S
TGT GCA GCA AGT
A A P N
GCA GCG
Va2
C A S S Q G
1 TGT GC AGC AGC CAA LGG
Vp1 Dpi
C A A S A A
41 a TGT GCA GCA AGT GCA GCG
Va2
Y N V L Y F G S G T K
CCT AAT TAC AAC GTG CTT TAC TTC GGA TCT GGC ACC AAA
Jal6
Y N S P L Y F A A G T R
TAT AAT TCG CCC CTC TAC TTT GCG GCA GGC ACC CGG
Jp1.6
P N Y N V L Y F G S G T K
CCT AAT TAC AAC GTG CTT TAC TTC CCA TCT GGC ACC AAA
Ja16
C A W N T G G A E T L Y F G S G T R
P TGT GCC TGG AAT ACT GGG GGG GCT GAA
Vp14 DpI
ACG CTG TAT TTT
Jp2.3
GGC TCA GGA ACC AGA
a- and -chain sequences of the TCRs from two 15-26-non-responders are
reported sequences of cell 41
for alignment. Assignment of
elements is from Koop, et al,
(Lai, et al, 1988) are shown for comparison.
V elements is based on Wilson, et al 1988.
1992. D element assignments are from Siu,
shown. The previously
Spaces are introduced
Assignment of J
et al, 1984.
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Response of cell 41 to substitutions at position 22
1 2-26
I
ala asp leu lys phe
position 22 substitution
Relative sensitivity of T hybridoma 41 to substitutions at 1 2-26
position 22. Half-maximal stimulatory concentration with un-
substituted 12-26 is 0.3 p. g/ml.
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Relative sensitivity of cells 31 and 51V to position 25
substitutions
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position 25 substitution
T cell 51V and 31 were tested for their sensitivities to substitutions at
position 25. Results are expressed as the inverse of the concentration of
each substituted peptide required for half-maximal stimulation,
normalized with respect to the sensitivity of each cell to 12-26
containing no substitutions. Half-maximal stimulatory concentration by
12-26 was 0.2gg/ml for cell 31, and 0.8gg/ml for 51V.
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Table 2.1 Peptide specificity of hybridomas produced by
immunization with 12-26 or cl protein
Immuno gen
Number of
hybrids screened
27cI
12-26 45
Response to
12-26 15-26
13
45
13
25
Lymph node cells taken 7 days after immunisation with antigen from CBA (k
haplotype) mice were fused with the thymoma BW5147a-p- (White, 1989)
Hybridomas responsive to the immunogen were screened against peptide 12-
26 and the truncated peptide 15-26. Cells classified as non-responsive to 15-
26 did not respond to concentrations as high as 50gg/ml peptide.
Table 2.2
Hybridoma
1.9
1.10
1.11
1.12
1.13
1.14
1.16
1.17
1.18
1.20
1.21
2.1
2.2
2.4
2.11
2.12
2.13
2.16
2.19
2.20
C26.4
3I
8I
10I
Peptide specificity of T hybridomas
Sensitivity to
Immunoaen 12-26 15-26
12-26 0.3gg/ml 0.2gg/ml
12-26 0.08 0.05
12-26 0.6 0.5
12-26 0.3 0.5
12-26 1
12-26 1
12-26 1
12-26 2
12-26 0.2 0.4
12-26 0.1 0.1
12-26 0.5
12-26 2
12-26 1 0.5
12-26 0.8
12-26 2
12-26 .06 0.05
12-26 2
12-26 2
12-26 0.4
12-26 2
12-26 .2 .2
cI .2 .1
cI .1 .1
cI .1 .07
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Table 2.3
Group
T cell receptor gene usage among 12-26-specific T cells
Cell Va V,
15-26-responders
1 5-26-non-
responders
31, 1.9, 1.20, 2.12
81
101
Va2
Va2
Va2
1.13, 1.16,
1.21, 2.13, Va2
VP 1
V 6
v, 8.3
V 1
2.16, 2.20
TCR gene usage was determined by PCR analysis as described by Lai,
et al, 1990. The TCR sequences of cells 31, 81 and 101 were previously
reported (Lai, et al 1990; Lai, et al 1988). PCR was performed in the
laboratory of Ming-Zong Lai, Insitute of Molecular Biology, Taipei,
Taiwan.
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Chapter 3
Abstract
A variety of evidence suggests that residues outside a T cell
epitope play a role in its antigenicity by affecting the efficiency
with which it is processed from a protein by antigen presenting
cells. In particular, the flanking residues have been hypothesized to
contain target sites for proteases. A number of proteases, in
particular, members of the cathepsin family, have been implicated in
this process. Several types of indirect evidence have been produced
to support this idea: 1) Treatment of a protein with one of these
enzymes leads to the production of peptides that can be recognized
by T cells without further processing, 2) Treatment of APC with
inhibitors of various proteases reduces the efficiency of antigen
presentation, and 3) Proteases have been identified in the
intracellular compartments where processing is believed to be
carried out. Nevertheless, no enzyme or set of enzymes has been
demonstrated to be essential for processing for all different
epitopes, and it has not been possible to identify consensus
sequences in proteins that might be the sites recognized by
proteases. In order to test the hypothesis that such consensus
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sequences exist flanking T cell epitopes and to characterize them if
they could be localized, we developed a system to screen cl variants
containing substitutions in the flanking regions of the
immunodominant epitope located between residues 12-26 for
substitutions that would affect processing. We find that the wild-
type amino acids can be replaced with significantly different
sequences for several residues on either side of the minimal epitope
without a decrease in the efficiency of processing. This result
suggests that the immediately flanking residues do not direct the
processing of 12-26. By contrast, two types of mutations were
found during the course of the study which did appear to alter the
processing of the protein. One, the substitution of an alanine at
position 20 with either valine or glycine apparently decreased the
efficiency of processing of 12-26. The other, a substitution in the
C-terminal flanking region of 12-26 led to an increased efficiency
of processing of both 12-26 and a second epitope within the protein.
These observations are compatible with two alternative hypotheses,
1) That processing is controlled by motifs lying internal to the T
cell epitope itself, or 2) That the mechanism of processing involves
an initial cleavage occuring distant to the epitope followed by a
trimming step to produce the mature peptide which binds MHC.
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Introduction
As we have previously mentioned, T cells, unlike B cells, do
not recognize protein antigens in their native conformation. For T
cell stimulation to occur, the protein must first be processed by
antigen presenting cells and the resulting fragments then appear on
their surface in association with a molecule of the Major
Histocompatibility Complex. This processing has not yet been well
characterized, but clearly involves proteolytic degradation as
peptides have been shown to substitute for intact protein antigen,
and some of the actual peptides bound by MHC molecules have been
purified and sequenced (Falk et al., 1991; Jardetzky et al., 1991;
Rudensky et al., 1991). This work has led to the identification of
peptide motifs which confer specificity of binding to different MHC
molecules. For a sequence within a protein to become a T cell
epitope, it must therefore be capable of binding to MHC. It is not
clear, however, whether such a condition is sufficient. Processing
may also play an important role in the selection of some epitopes
and the loss of potential ones. Indeed, a great deal of evidence has
accumulated indicating that this the case. Substitutions in proteins
and peptides outside of class 11-restricted T cell epitopes have
occassionally been shown to alter the response to the epitopes
(Gammon, et al., 1987; Liu, et al., 1991; Shastri, et al., 1986;
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Vacchio, et al., 1989). Furthermore, treatment of antigen presenting
cells with inhibitors of various proteases has been shown to modify
the presentation of class Il-restricted epitopes (Diment, 1990;
Takahashi et al., 1989; Vidard et al., 1991). Most recently the
presentation of a class I-restricted epitope has been shown to vary
according to the site of its insertion into a heterologous protein (Del
Val, et al., 1991). These data suggest that in both the class I and
class II antigen presentation pathways particular structural
features within a protein are necessary for proper processing and
presentation. Such features may be local, for example specific
sequences flanking the epitope necessary for its proper excision by
proteases or may relate to the position of the antigenic sequence
within the global structure of the protein. In the present work we
describe a test of the hypothesis that flanking residues contain
specific sequences that direct the processing of class II restricted
epitopes.
The 12-26 epitope of cl is advantageous for this study for
two reasons. First, this sequence is immunodominant in two
disparate haplotypes (d and k) (Lai et al., 1987), which may be
consequence of a conserved cellular processing machinery. Second, a
system of cassette mutagenesis has been developed which permits
the facile modification of the cl protein (Reidhaar-Olson and Sauer,
1988) and an exhaustive study has been conducted to determine the
structural and functional consequences of substitutions at various
positions (Reidhaar-Olson & Sauer, 1990), thus, the effects on the cl
protein of many substitutions are already known.
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Our assumption in conducting these experiments is that if
there are specific sequences in the flanking residues of 12-26 which
direct its processing, they should be relatively restrictive in terms
of the number and types of substitutions they will accept. Most
substitutions introduced into such sites should therefore lead to
their destruction, and consequently, a diminished efficiency of
processing of the 12-26 epitope. Using the cassette mutagenesis
system described above and adding to it a simple method for
screening the T cell response to the cl protein expressed in E. coli
we have measured the effect of substitutions in the regions flanking
the 12-26 epitope. This approach would provide an additional
advantage in the event where a processing site could be localized. In
this case, further mutagenesis of the identified sequence could be
used to precisely characterize the motif recognized.
The results indicate that a wide variety of different amino
acids can be substituted in the positions flanking 12-26 without
significantly decreasing the effectiveness of processing. This
indicates that the immediately flanking residues are unlikely to
contain precisely defined sequences that are recognized by putative
processing enzymes. Consequently, these data favor a model of
processing where initial proteolytic cleavage of a protein occurs
relatively distantly to the epitope, followed by trimming to produce
the mature peptide which is bound by MHC, or a model whereby the
processing of the epitope is controlled by sequences lying within the
epitope itself. This second possibility is suggested by the
identification during the course of the study of two proteins whose
processing did differ from wild-type cl. Both proteins contained
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substitutions for the wild-type alanine at position 20, in one case to
glycine, and in the other to valine. These substitutions led to a
decreased efficiency of processing of 12-26 relative to another
epitope in the protein.
A second mutant whose processing was altered compared to
the wild-type protein contained several substitutions at residues
24-27 which appears to lead to an increased efficiency of
processing of at least two epitopes in cl. These mutants represent
potential tools for the further analysis of antigen processing.
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Results
The peptide corresponding to residues 12-26 of cl has been
shown to stimulate T cells specific for cl in two different
haplotypes (d and k). The "natural" peptide actually bound to the MHC
molecule is not known however. Thus, in order to modify the
residues flanking the epitope, the minimal peptide capable of
stimulating two I-Ad-restricted T cells (denoted 24.4 and 26.2) was
determined. As shown in Figure 3.1, 24.4 responds well to a peptide
corresponding to residues 12-23, but the response is significantly
diminished by the loss of either residue 12 (P13-24), or residue 23,
(P12-22). Cell 26.2 has a slightly different minimal peptide
requirement. It responds approximately ten-fold less well to P12-
23 than to P12-26. Both cells therefore require residue 12 for
maximal stimulation, although they differ in their C-terminal
requirements. Peptide 12-23 appears to be capable of binding class
II MHC because it maximally stimulates cell 24.4. The length of this
peptide is slightly shorter than the size of peptides (13-17aa) that
have been eluted from class II molecules (Rudensky et al., 1991).
Residues which may influence processing should therefore be
predicted to lie outside this sequence.
If a motif required for processing exists bordering this
epitope, its length and stringency at each position is not known. We
therefore developed a technique to permit the rapid screening of
different amino acid substitutions in the several residues adjacent
to residues 12-23. Our goal was to derive a method to screen a
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large number of protein mutants with a minimal level of purification
in order to identify likely candidates for processing mutants that
could subsequently be purified and studied in greater detail.
Furthermore, such a technique would aid in the characterization of a
processing site, in the event where one could be localized. First, a
test was conducted to determine whether lysates from bacteria
expressing cl could be directly assayed for the presence of the
protein without the need for purification. Such lysates might, for
example, contain either toxins or factors inducing non-specific
stimulation of T cells that would interfere with a screen. E. coli
carrying a plasmid for the expression of cl were grown in liquid
culture, induced to express the protein and a crude lysate was
prepared from the cells (See Materials and Methods for details). T
cells in the presence of antigen presenting cells were then tested
for stimulation by various dilutions of this lysate. Figure 3.2 shows
that a crude lysate prepared in this manner can specifically
stimulate both 26.2 and 24.4. At the highest concentrations, roughly
10% and above, the lysates are indeed toxic. At roughly 5%, however,
maximal stimulation occurs. Neither cell is stimulated
significantly by a lysate prepared from bacteria which does not
express cl. Furthermore, based upon the extent to which the lysate
can be diluted before stimulation drops to background levels, a 5%
lysate contains approximately 10-20 times the amount of protein
necessary for detectable stimulation (Figure 3.2). This therefore
suggested that E. coli lysates containing cl mutants could be
directly screened for stimulation of T cells without the need to
purify the proteins individually.
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Ad-restricted T cells have been found using peptides to be
sensitive to substitutions at position 20 of 12-26 (A.S.,
unpublished). This observation was used to confirm that lysates
could be screened for mutations in cl that lead to a decreased
stimulation of 12-26-specific T cells. Random cassette
mutagenesis was employed to create a bank of cl mutants containing
various substitutions at position 20. Crude lysates from bacteria
expressing these proteins were prepared as above and tested
directly for the stimulation of T cell 26.2. The level of protein
expression was confirmed by SDS gel and found to be similar for the
mutants and wild-type cl (not shown). After DNA sequencing to
determine the amino acid substitution at position 20, the results
were compared to the stimulation induced by peptides containing
the same substitutions. Figure 3.3 shows the stimulation by 5%
lysates containing various cl mutants to the relative stimulation by
peptides containing the same substitutions. Unexpectedly, there are
significant differences between the results obtained. Peptides with
two of the substitutions, glycine and valine, stimulate 26.2, while
the corresponding proteins do not. The response to the former may
reflect the limits of the screening process in that the same
substitution in the peptide leads to a response which is diminished
compared to P12-26. Significantly however, two different proteins
containing valine substitutions were found not to stimulate, while
the same substitution in the peptide does not diminish the response.
This difference between the response to the protein and the peptide
containing the same substitution could indicate the identification of
proteins whose processing is modified. One report exists in the
93
literature of a mutation within the epitope which diminishes the
efficiency of processing (Finnegan and Amburgey, 1989).
To investigate this further, these proteins and the wild-type
were purified. While the response of 26.2 to 12-26 and 12-26(V20)
is essentially the same (Figure 3.4A), the response to the purified
protein containing the valine substitution is diminished
approximately 50-fold compared to the wild-type (Figure 3.4B). To
demonstrate that this diminished response is particular to the 12-
26 epitope, the response of a second cell specific for an epitope
located between residues 46-62 was also determined. As can be
observed (Figure 3.4B), this cell responds equally well to the valine
mutant as to the wild-type.
Based on the results presented in Figure 3.3, the mutant
containing glycine at position 20 may also be processed less
efficiently than wild-type. This is difficult to evaluate with cell
26.2, however, because it also responds less well to the peptide
containing the glycine substitution. Cell 24.4 also responds poorly
to this peptide. An Ek-restricted cell, C26.4, has been identified
which responds approximately equally to P12-26(G20) and P12-26
(Figure 3.5A). This cell and A128 were tested against cl(G20). The
results are displayed in Figure 3.5B. As was the case for cell 26.2
with cl(V20), cl(G20) has greatly reduced stimulatory activity for
C26.4, despite the fact that the peptide containing the same
substitution stimulates comparably, if not better than P12-26.
Again, A128 responds equally well to the two proteins. These
results, therefore, strongly suggest that these two substitutions
alter the processing of the 12-26 epitope from cl protein.
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Furthermore, it is significant that mutations at the same position
appear to modify the processing of cl as measured by T cells of
different haplotype restrictions (Ad and Ek). This implies that
processing occurs by a mechanism independent of the interaction of
the peptide with MHC.
Several alternative explanations for the results observed were
considered, and experiments were conducted to eliminate them.
First, the effects of the substitutions at position 20 are unlikely to
be due to a degradation of the protein unrelated to antigen
processing. The mutant and wild-type proteins elute from ion
exchange columns at the same salt concentration during purification
indicating that the structural and biochemical properties of the
mutant are not significantly altered. Furthermore, cl has been the
subject of an exhaustive mutagenic study (Reidhaar-Olson & Sauer,
1990). Position 20 has been found to accept a variety of amino acid
substitutions, among them glycine, without impairment of its
function as a repressor of -phage. We have confirmed this by
testing the ability of the mutant cl proteins to protect E. coli from
lysis by a series of X-phage mutants varying in lysogenicity (Hecht
and Sauer, 1985). The effectiveness of the mutants is
indistinguishable from wild-type in this test (not shown). Finally,
the difference between the behavior of the wild-type and mutants is
not due to an error that might have intervened during the process of
cloning and sequencing. The proteins themselves have been
sequenced and contain no other differences from wild-type within
the first 26 amino acids. We conclude that the effect seen is most
likely due to a reduced efficiency of processing of the 12-26 epitope
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in the mutant protein. Experiments aimed at determining the means
by which these mutations affect the processing of the 12-26 epitope
will be described below.
The identification of mutations affecting processing at
position 20 of cl suggests the possibility that processing is
controlled by motifs lying within the epitope. For example, the
effect of the substitutions may be to destroy a sequence which is
essential for the correct processing of the 12-26 epitope.
Alternatively, substitutions may lead to the creation of a processing
site which would cause the cleavage of the protein during processing
and the consequent loss of the epitope. In the latter case, the
normal processing of the epitope might still be controlled by the
flanking residues. In order to evaluate this second possibility, we
applied the same technique to screen the protein for mutations at
positions N-terminal to the epitope that might affect processing.
As the leucine at position 12 had been found to be essential for both
cells 24.4 and 26.2, the effect of the four residues preceding this
position was evaluated. In this case the mutagenesis was performed
at pairs of positions, that is, substitutions were introduced at
either positions 8 and 9, or 10 and 11. Lysates from bacteria
expressing the mutant proteins were prepared and tested for the
stimulation of cell 26.2. Table 3.1 gives the relative stimulation
induced by 20 such mutants, along with the changes that have been
made in the protein. In contrast to what was observed for mutations
at position 20, although a wide variety of different amino acids have
been introduced at positions 8-11, the majority of the mutants
stimulate comparably to the wild-type protein. At positions 8 and
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9, replacement of the the wild-type threonine-glutamine with pairs
of amino acids as disparate as glycine-arginine, histidine-glycine or
proline-proline does not seem to prevent presentation of the epitope.
Similarly, at positions 10 and 11 a wide variety of replacement
amino acids is allowed. If indeed a motif controlling processing is
present in the wild-type sequence bordering the epitope one would
expect the majority of these sequences not to conform to it and thus
to impair proper processing. Initial comparison of this result,
therefore, contrasts significantly with that obtained by mutagenesis
at position 20, where dramatic differences occurred depending upon
the substitution. This suggests that no such motif exists at these
positions.
The range of acceptable amino acid substitutions at positions
8-11 which maintain the functional integrity of cl has previously
been studied by the group of R.S. Sauer (Reidhaar-Olson & Sauer,
1990). Table 2 also includes the effect of the mutations we have
introduced on the structure of cl based on this work. As is the case
with the primary structure in the residues flanking the epitope, no
correlation can be drawn between the effectiveness of presentation
and whether a given set of substitutions affects the overall
structure of the protein.
To eliminate the possibility that these results are the
consequence of a lack of sensitivity of the screening technique, a
number of the most likely candidates for processing mutants were
purified and tested for stimulation of T cells 26.2 and A128. By
comparing the dose-response curves for stimulation of these cells
by the various mutants, we hoped to identify more subtle
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differences in processing that may have escaped our initial screen.
Among the proteins purified and tested were mutants number 14 and
16 which had been among the weakest stimulators in the screen. As
can be seen in Figure 3.6 some variations do occur in the stimulation
26.2 by the various mutants. These are generally small, however,
roughly a factor of 4 for the most significant effect. As these
effects are small compared to those observed for changes at
position 20, we conclude that no sequence motif necessary for
processing exists in the N-terminal region immediately bordering
the epitope.
A similar screen was carried out among proteins mutated in
the C-terminal flanking region of the epitope, using a slightly
different procedure. As the T cells 24.4 and 26.2 had been found to
have different minimal peptide requirements, mutagenesis was
carried out for positions 24-27 and the proteins produced were
simultaneously screened for stimulation of both T cells. In this way
the differential responsiveness of the two cells to substitutions at
position 24 could be expected to serve as an internal control for the
sensitivity of the screen. In this case all four residues were
simultaneously randomized. Table 3.2 shows the relative
stimulation in such a screen of 24.4 and 26.2 by 27 such mutants and
the substitutions they contain. As was the case for the mutants at
positions 8-11, the differences in the stimulation of the T cells are
relatively minor and proteins containing vastly different
substitutions stimulate one or both T cells essentially as well as
wild-type. As expected, in some cases one T cell was stimulated
significantly more stongly than another by a given mutant (for
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example, mutants 7 and 12). Based on studies using peptides
substituted at position 24, this can be accounted for by differences
in the acceptance of replacement amino acids at this position by the
two T cells (not shown). 26.2 does not respond to a peptide
containing aspartate at position 24, while 24.4 does at nearly the
same level as to the wild-type peptide. That similar results are
obtained for the protein indicates that the naturally processed
peptide probably includes residue 24.
Once again, several of the most likely candidates for
processing mutants were purified and tested in parallel for
stimulation of 26.2 and A128. As shown in Figure 3.7, all of the
proteins except mutant 20 stimulate both 26.2 and A128 similarly
when purified protein is used. These results, then, combined with
those obtained with proteins substituted at positions 8-11 lead us
to conclude that no strict motif that controls the processing of this
epitope is located in either the N-terminal or C-terminal flanking
residues. Interestingly, however, mutant 20 stimulates 26.2
roughly 5-fold better than wild-type protein. This effect is not
likely to be due to an altered binding of the epitope to MHC or T cell
receptor because the stimulation of A128 is similarly increased.
Rather, it appears to be due to a modification of the processing of
the protein as a whole.
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Discussion
Antigen processing could occur by one of several
conceivable mechanisms: 1) It could, for example, be a random
process whereby non-specific proteases cut the protein with no
sequence specificity whatever. Such a mechanism would require
that the concentration of the enzymes are dosed so as to prevent the
total digestion of the protein. Furthermore, the concentration of any
particular peptide produced would be extremely low, which would
have the ultimate consequence of limiting the sensitivity of the
immune response to the protein. It would also be in contradiction
with observations that cellular processing compartments contain
proteases with sequence specificity (Guagliardi et al., 1990), and
that specific inhibitors of proteases prevent the presentation of
certain epitopes (Diment, 1990; Takahashi et al., 1989; Vidard et al.,
1991). A second possibility has been suggested by the work of Allen
and colleagues (Donermeyer and Allen, 1989), in which it was
demonstrated that binding of a denatured protein to MHC protects
the bound portion from digestion by a protease (chymotrypsin). In a
model based on this observation, one can imagine processing
proceeding by the denaturation of the protein under the acidic
conditions of the endosome, followed by binding of certain segments
to MHC, followed by trimming of all parts not protected by MHC,
again by non-specific proteases. This model would be compatible
with the idea that sequences within the epitope itself direct
processing. However, it would not be compatible with our
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identification of mutations at position 20 that alter processing of
cl, because in this case the fact that the peptide containing the
same substitution is presented indicates that this substitution does
not affect binding to MHC. In a third model, protein antigens could
first be digested by specific proteases into relatively long peptides,
followed by binding to MHC and subsequent trimming by non-specific
proteases to produce mature peptides. This model would be
compatible with the existence of specific proteases in putative
processing compartments (Guagliardi et al., 1990), could explain
why specific inhibitors of proteases can block presentation of some
epitopes (Diment, 1990; Takahashi et al., 1989; Vidard et al., 1991),
and would be in agreement with the observation that peptides eluted
from MHC class II proteins have different C-terminii indicating a
trimming step has occurred (Falk et al., 1991; Jardetzky et al., 1991;
Rudensky et al., 1991). Finally, in a fourth model one can envision
that the flanking residues of T cell epitopes contain specific
sequence motifs which are recognized by processing enzymes. This
model would explain the observation that certain protein antigens
digested in vitro by proteases implicated in processing (the
cathepsins B and D) can stimulate T cells without the need for
further processing (Takahashi et al., 1989; Van Noort, et al., 1991).
The present work was conducted to test the fourth hypothesis
described above. In order to do so we have introduced random amino
acid substitutions for several residues on either side of a minimal T
cell epitope and have found that the presentation of the epitope
remains comparable to that of the wild-type. We conclude,
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therefore, that in the case of the 12-26 epitope proper processing is
not determined by the immediately flanking residues.
This conclusion is based on several assumptions. First, if
specific sites recognized by proteases do exist flanking T cell
epitopes, they should have relatively restrictive sequence motifs.
Therefore, the majority of substitutions introduced into these sites
should lead to their destruction, and a consequent reduction in the
processing of the epitope. We find that a large variety of different
amino acids can be substituted at the several positions flanking an
epitope and the epitope is still presented effectively. An
alternative approach has been used by another group to study
processing of a class I restricted epitope (Del Val et al., 1991).
These workers inserted an epitope at different sites in a
heterologous protein, and found that the efficiency of processing did
indeed depend upon the site of insertion. This approach suffers from
the limitation that it may be difficult to distinguish the effect of
the protein environment on the fate (processing) of the epitope from
the effect of the insertion of the epitope on the fate of the protein
i.e. degradation, compartmentalization, etc. It was for this reason
that we chose the approach of modifying only the surrounding
residues, while keeping the overall protein environment the same.
The different conclusions obtained by these authors and ourselves
may reflect the use of the different approaches chosen, or, more
probably, the different mechanisms of class I and class II
processing.
A second assumption is that the sequences recognized by
processing enzymes are located close to the epitope. The criticism
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might be made that mutagenesis was not performed far enough from
the epitope in order to identify processing motifs. However, as the
length of peptides eluted from class II molecules has been between
13-17 amino acids (Kropshofer et al., 1992; Rudensky et al., 1992;
Rudensky et al., 1991), the 20 amino stretch (residues 8-11 and 24-
27) examined here should have identified them. Therefore, these
results argue against processing occuring only by specific cleavage
of protein antigens without subsequent trimming.
Finally, our conclusion is based upon the assumption that the
effects of mutations that interfere with processing would cause a
significant decrease in the stimulation of T cells. The initial screen
employed using lysates of bacteria expressing variants of cl
probably would not have been able to detect small effects on the
efficiency of processing. However, a number of the proteins giving
the lowest stimulation in the initial screen were purified and found
to stimulate comparably to the wild-type protein. Some small
effects on the response of T cells to these proteins were observed
(on the order of a factor of 4). However in a number of cases,
residues in a peptide outside a minimal epitope can be shown to
affect the response of T cells. For example, hybridoma 24.4 does not
require residue 24 for maximal stimulation, but responds
significantly less well to a peptide containing a aspartate
substitution at this position (not shown). Furthermore, the fact that
the two mutants containing substitutions at position 20 were
identified, suggests that the system is sensitive enough to detect
mutations that do cause veritable reductions in processing
efficiency. The effects of these two mutations, an apparent
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reduction in processing efficiency of 20-50-fold, demonstrates that
these effects are significant.
A surprising finding was the identification of these two
proteins from which the 12-26 epitope is apparently processed less
efficiently than from the wild-type protein. Both of these proteins
contain changes at position 20 of cl, in one case from alanine to
valine, and in the other to glycine. This conclusion is based upon the
observation that peptides containing the identical substitutions
stimulate T cells comparably to 12-26. These proteins represent
useful tools for the characterization of the mechanism of
processing.
If processing occurs by the recognition of specific sequences,
these mutations would be presumed to modify processing either
creating or destroying a cleavage site. A number of attempts have
been made to identify such sites, both by sequence comparison and
by experiment. The replacement of the alanine at position 20 with
either a glycine or valine neither creates nor destroys an obvious
site for either Cathepsin B, or Cathespsin D, the two enzymes most
commonly implicated in processing. Cathepsin D cleaves
preferentially between the amino acid pairs phe-phe, phe-tyr or leu-
phe (Offerman, et al., 1983). The role of Cathepsin B in antigen
processing is implied both by its presence in endosomes (Guagliardi
et al., 1990), and the demonstration that myoglobin digested with
the enzyme can be presented to different T cells without the need
for further processing (Takahashi et al., 1989). It appears to cleave
after an arginine (Bond & Butler, 1987), but has also been shown to
have a peptidyldipeptidase activity, cleaving dipeptides from the C-
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terminus (Aronson and Barrett, 1978; Bond and Barrett, 1980). A
number of experiments have been conducted to evaluate the
possibility that either Cathepsin B or D cleaves the wild-type and
position 20 mutants differently. To date we have been unable to
detect differences in the pattern of peptide fragments produced by
either of these enzymes using SDS-PAGE. More recently, a third
enzyme, Cathepsin E, has been shown by the use of specific
inhibitors to be essential for the processing of ovalbumin (Bennett
et al., 1992). Experiments are currently planned to test the
possibility that the position 20 variants are differentially cleaved
by this enzyme.
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Table 3.1
Stimulation of T cell 26.2 by cl proteins containing substitutions
at positions 8-11
Position
9 10 11
Arg
Gly
Pro
Ser
Arg
Pro
Arg
Thr Gln
Trp
ND
Leu
Phe
Ala
Ser
ND
ND
Gly
ND
Cys
Arg
Glu
Relative Simulation
0.06
0.23
0.68
0.99
0.78
0.75
0.43
0.73
p 0.25
0.29
J 0.7
1 0.7
r 0.54
e 0.19
0.48
0.15
1 0.71
0.05
e 0.18
0.82
1 1
Protein
Conformation
ND
ND
ND
Response of cell 26.2 in a screen of E. coli lysates containing
mutants with substitutions at positions 8-11. Responses are
relative to the response to a lysate from E. coli expressing wild-type
cI. Protein conformation refers to whether the indicated
substitutions are expected to inhibit the function of cI as a
repressor of -phage based on the results of Reidhaar-Olson and
Sauer, 1990.
8
STOP
Gly
His
Pro
Ile
Tyr
Pro
Trp
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
WT
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Table 3.2
STIMULATION OF T CELLS BY cl MUTANTS CONTAINING
SUBSTITITUTIONS AT POSITIONS 24-27
SUBSITUTUTION AT
POSITION:
26 2724 25
ND
LYS LEU
ND
ND
ND
ND
ASP LEU
ND
SER LYS
ND
ND
ASP LYS
LEU LEU
ND
ND
ND
ASN
GLY
GLY
ILE
ARG
ARG
PRO
ASN
LYS
D
STOP
ND
SER
THR
ARG
PRO
GLY
SER
ARG
ND
GLN
LYS
LYS SER
ARG MET
THR CYS
VAL
LYS
GLN
ALA
PRO
THR
ARG
ARG
THR
VAL
LYS
RELATIVE STIMULATION
OF
24.4
1.52
0.49
2.99
3.28
3.67
2.08
0.33
1.02
0.04
1.18
0.46
1.89
0.01
3.22
0.26
0.31
0.16
0.01
0.61
2.93
0.45
1.01
1.19
0.83
2.84
0.28
2.96
1.53
1
0.01
LYS
HIS
TYR
CYS
LYS
PRO
VAL
PHE
ASN
VAL
ASN
NEGATIVE CONTROL
T CELL:
26.2
0.88
0.78
0.97
0.96
1.12
1.01
0.01
1.02
0.03
0.27
0.7
0.01
0.01
0.94
0.41
0.83
0.57
0.00
0.33
0.87
0.01
0.06
0.81
0.86
1.04
0.36
1 .08
0.06
1
0.00
Results represent the response of T hybridomas 26.2 and 24.4 to a
screen of 5% lysates from E. coli bacteria expressing the indicated
cl mutants. Responses are the average of duplicates, and are
normalized with respect to the response to a lysate containing
wild-type cl.
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Concluding Discussion
Since the experiments described here were performed, a
number of important findings relating to antigen presentation have
been made. The most important of which is the crystallization of
the human HLA-DR1 class II antigen (Brown et al., 1993). Despite
the numerous differences in primary structure between the HLA-
DRAI molecule and Ek, the crystal structure illuminates a number of
the findings described here. First, the structure explains the more
heterogenous length of class I-restricted peptides compared to
their class I-restricted counterparts. While the amino terminus of
the class I ai domain contains two turns which effectively block the
N-terminal end of the peptide binding groove, in the equivalent
portion of the class II structure these are replaced with extended
chains that leave the groove open. Another difference in structure
leaves the C-terminal end of the groove open as well. The direct
consequence of these differences is to allow larger peptides to bind,
extending out from the ends of the class II molecule much as a
hotdog in a bun. This explains the observation that the average
length of peptides eluted from class II molecules is 14-15 amino
acids(Rudensky et al., 1991; Rudensky et al., 1992) Furthermore, as
many as 15 amino acids of the peptides bound in the class II groove
contact HLA-DR, although the tightness of the interactions at each
position is variable. This supports the observation made here that
at least some substitutions at every position of 12-26 could affect
binding (Chapter 1). Furthermore, a number of contacts appear to
exist between conserved residues of the class II molecule and
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peptide backbone, again supporting the observation that
substitutions at a number of positions could affect binding by subtle
alterations in the conformation of bound peptide.
Only a single side chain pocket is found in the structure. This
is in agreement with the observation that an HLA-DR1-restricted
peptide with all residues but ones substituted to alanine retains
MHC binding(Jardetzky et al., 1990). The Ek structure should
therefore contain a pocket to stabilize the hydrophobic residue
corresponding to the leucine at position 18 of 12-26. A second
pocket containing a negatively charged residue is likely to exist in
the Ek structure to account for the preference for positively charged
residues at position 26.
Contrary to the case in the class I HLA-A2 and HLA-Aw68,
where peptides fit into the structure by bulging out in the
middle(Silver et al., 1990; Madden et al., 1991), there is no weak
electron density in the middle of the class 11-bound peptide. If this
proves to be general for all class II molecules, it would be in
disagreement with the Ek-binding motif proposed in Chapter 1 which
invoked a variable 7-8 space between the two anchor residues.
However, in the class I B27 structure, no apparent bulging of the
peptide was observed(Madden et al., 1991). Thus, it may be the
tendency of peptides to adopt a bulging conformation is not unique to
class . The strong electron density from the bound peptide
indicates that the peptide is held in a unique conformation and
supports the conclusion reached here that peptides are not likely to
bind to class II in multiple conformations. Since the bound material
is a mixture of endogenous peptides, it represents an effective
117
sampling of a variety of peptides. Thus, if an appreciable number of
peptides were oscillating between alternative conformations, one
would expect to see a correspondingly lowered electron density.
Additional support for this conclusion comes from an NMR study of a
cytochrome C peptide bound to Ek. Although the resolution of this
technique is not yet equal to that of crystallography, because it is
much less time consuming to apply to each new structure, it
probably represents the wave of the future for for understanding of
peptide MHC interactions. In this study, the cytochrome C peptide
was 1 3C-labelled at each position along the backbone. Definitive
assignments of the peptide residues accounting for binding could not
be made in all cases, but single cross-peaks were obtained for each
residue, indicating that the peptide was bound in a unique
conformation (Driscoll et al., 1993).
The manner in which the peptide is bound in the class II
structure also lends some support to one proposed mechanism of
antigen processing (Donermeyer and Allen, 1989). As mentioned in
Chapter 3, antigen processing could occur by an initial denaturation
of proteins, followed by binding to the class II molecule, followed by
the proteolytic digestion of unprotected portions. Such a model is
not possible for class I-restricted peptides because the closed form
of the binding groove prevents longer peptides from binding. It is
important to note, however, that this model could not explain the
antigen processing mutants identified here. If this model were true
in its simplest form, all peptides capable of efficiently binding MHC
would also be efficiently processed. Since the mutations we have
identified lie within the epitope do not significantly affect the
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capacity of synthetic peptides to bind MHC, they would, according to
this hypothesis, still be properly processed. These observations
could, however, be explained by a model involving first an initial
cleavage step distant from the epitope, followed by binding and
trimming to a final size.
One particularly puzzling observation made in this work was
that there were several cases of T cells which gave maximal
responses to peptides which are predicted by the competition
binding experiments to bind weakly to Ek. For example, T cells
C26.4, 1.21, and 2.19 all respond well to 12-26(Y26), even though
this peptide has no detectable activity as a competitor. These
results are paradoxical in that the peptide should ordinarily be
incapable of stimulating all T cells if it cannot bind MHC. Such an
observation could have a variety of explanations. The simplest is
that these substitutions simply increase the affinity of the the TCR
for the peptide-MHC complex, either by adding a productive
interaction with the TCR or removing an unproductive one. As the T
cells were originally selected upon immunization only for having a
minimal affinity for the complex, it is probable that some changes
in the sequence of the peptide or MHC structure could augment this
affinity. Such a situation would be analogous to the process of
somatic mutation that occurs to refine the affinity of antibodies
after an initial immune response. However, in this case, it would
not be the immune receptor (the TCR), but the ligand which was
modified.
Alternatively, this result may be explained by differences
between the experimental protocols used to measure MHC binding
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(competition) and T cell stimulation. In the former, fixed APC are
used. Binding of peptide occurs on the surface of the cells at the
neutral pH of the tissue culture medium. In the latter, binding may
occur either on the surface of the cells, or intracellularly, after
endocytosis. The pH of the compartment where peptide binding to
MHC is believed to occur is estimated at 4.7 to 5.2 (Mellman et al.,
1986). The binding of some peptides to purified MHC has been shown
to be a maximum at a pH in this range(Wettstein et al., 1991). Other
factors besides the pH may also affect the intracellular binding of
peptide to MHC. One particularly intriguing possibility is suggested
by the detection of PBP72/74, a member of the hsp70 molecular
chaperone family in endocytic vesicles (Lakey et al., 1987;
Vanbuskirk et al., 1989). These proteins, all of which identified to
date are ATPases, have been shown to be involved in the assembly of
newly synthesized proteins in the cell, as well as in protein
transport and perhaps protein degradation(Rothman, 1989).
PBP72/74 has been suggested to function at the site of antigen
processing to capture peptides and facilitate their with MHC
molecules. It is therefore possible that the binding of peptide
antigen to class II molecules in living cells is an active process that
occurs with greater efficiency than on the surface of cells. Thus, if
intracellular binding of a given peptide occurs more readily than on
the exterior of cells, the competition experiments may
underestimate the binding capability of the peptide under
physiological conditions. Experiments were performed to consider
the possibility that such enhanced binding efficiencies are at the
origin of the contrasts in the peptide competition and stimulation
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data. If this hypothesis is correct, this should be revealed by a
difference in the titration curves of T cells for some peptides when
fixed or un-fixed APC are used. However in experiments of this
type, no difference was observed in the sensitivity of T cells to
fixed or un-fixed cells. The original conditions of fixation used in
the competition binding experiments were such that the same dose-
response curves were obtained using 12-26 with either fixed or un-
fixed APC.
A further possibility is that the presence of the peptide-
specific T cell in the stimulation experiments may actually
facilitate the binding of the peptide to MHC. In the stimulation
experiments 12-26-specific T cells, APC and 12-26 analogs were
added simultaneously. Antibodies specific for MHC molecules have
been shown to enhance their interaction with peptides, and it has
been proposed that a weak interaction can be established between
TCR and MHC, facilitating peptide binding (Bodmer et al., 1989). If
such an interaction exists, it is conceivable that it could accelerate
the kinetics of binding of peptides to MHC on the surface of the APC.
In contrast, in the competition binding experiments, the T cell used
is not specific for the competitor peptide used, and should therefore
not facilitate its binding to MHC in any way. Thus, in this case the
stimulation experiments would overestimate the real physiological
binding capability of a peptide to MHC that would normally occur
intracellularly, and in the absence of T cells. In order to evaluate
the this hypothesis, the following experiment was performed. T
cells were preincubated for several hours with APC to allow
possible weak interactions between the TCR and MHC molecules to
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develop. A dilution series of 12-26 was then added to these cells.
As controls, the same dilution series was added to APC at the same
time as T cells. If indeed weak interations between the TCR and MHC
can facilitate the binding of peptides to MHC, one would expect a
lower concentration of peptide to be required for stimulation when T
cells are preincubated with APC. However, this was not the case.
Similar titration curves were obtained whether T cells were
preincubated with APC before the addition of peptide or
simultaneously.
Finally the observation, mentioned above, that MHC class II
molecules crystallize as dimers (Brown et al., 1993), may shed light
on this phenomena. This observation, supported by a growing body of
functional data, suggests a mechanism by which the affinity of T
cell receptors for peptide-MHC might be enhanced. According to the
hypothesis proposed by these authors, TCRs recognizing identical
peptide-MHC complexes would be drawn together by the dimer
interactions on the class II molecule. These interactions may be
supplemented within the plane of the TCR membrane by additional
weak interactions between the TCR molecules and co-receptor CD4
molecules. The combined action of these forces would then lead to a
sort of aggregate at the site of interaction between the T cell and
APC that would have a greatly enhanced avidity with respect to the
simple interaction between a single TCR and class II-peptide
complex. As receptor dimerization plays an important role in
intracellular signalling, the nature of the signal sent may be highly
dependent upon the avidity of this complex. The formation of such a
proposed three dimensional complex may be qualitatively different
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in the presence of competitors. Competitor peptides could, for
example, "poison" some class II molecules in the aggregate leading
to less efficient receptor interactions in the plane of the membrane
and consequently less efficient signalling.
The above-described caveat is particularly important in view
of the observation that analogs of a given peptide can inhibit T cells
not by competition at the level of MHC, but by competion of the
analog-MHC complex for binding to the TCR(De Magistris et al.,
1992). Thus, the nature of the antigen recognized by the TCR is more
sophisticated than previously thought. It is becoming more and more
clear that the TCR is does not simply signal or fail to signal
depending upon whether it binds antigen or not. De Magistris and
colleagues showed that some peptides closely related to that for
which a given T cell is specific can act as much more effective
inhibitors of T cell activation than more distantly related peptides
that bind MHC with the same affinity. In this case, the more
effective inhibitors appear to be acting as antagonists of the T cell
receptor itself. Thus, while the complex of these peptides with MHC
is bound by the T cell receptor, the receptor fails to signal. The
reason for this more effective inhibition has to do with the
minimum number of peptide-MHC complexes that must be recognized
by the T cell for stimulation to occur. Because this number is small
- on the order of 50-300 (Demotz et al., 1990), corresponding to
approximately 0.1% of MHC molecules on the surface of the antigen
presenting cell, peptides that compete by blockading MHC must
occupy nearly 100 % of MHC molecules. By contrast, it is found
empirically that a ten-fold excess of peptides that compete by
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acting as antagonists of the TCR can prevent T cell activation. Thus,
in this case, only 1 % of MHC molecules need be occupied. Thus,
competitors of this type are more powerful, are likely to be more
specific for a given type of T cell, and potentially more clinically
useful.
A similar, but mechanistically distinct phenomena has been
studied by Allen and co-workers (Evavold and Allen, 1991; Sloan-
Lancaster et al., 1993). In their initial study, they found that
peptides differing from the immunogenic peptide by some single
amino acid substitutions induced cytokine secretion, but not
proliferation. This "partial activation" appears to be the result of a
differential signalling capacity of the TCR depending upon the nature
of the ligand recognized. While these peptides appeared to have a
reduced affinity for the TCR, simply increasing the concentration of
peptide did not lead to proliferation. Thus, the authors speculated
that this differential signalling capacity is due to an altered balance
between the signal delivered by the TCR and other co-receptors such
as CD4 or CD3. These results were enlarged upon in a second paper
where it was shown that T cells treated with some peptides that
induced partial activation subsequently became unresponsive to the
original immunogenic peptide for extended periods. The
identification of partial activating peptides would therefore be
potentially even more powerful than that of TCR-antagonist peptides
because it would not require the continuous presence of the peptide.
In their study, De Magistris et al. found the TCR-antagonist
peptides with relatively high frequency. Among a set of 54 analogs
tested, at least 4 were active. Thus in the set of peptides tested in
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Chapter 2, we can presume that a certain number also can act as TCR
antagonists. In light of these findings number of significant
questions can be asked. First, for the moment, the capacity of
peptides to act as TCR antagonists has been demonstrated only for T
cell clones. As the co-stimulatory signals that are required for
clones and T cell hybridomas are different (Schwartz, 1992), it will
be important to determine whether TCR antagonists can be found for
the hybridomas studied here. It will be interesting to return to the
panel to see if correlations can be found between the location of
substitutions permitting an analog to act as a competitor for a given
T cell and the group (15-26-responder or non-responder) to which
the cell belongs. For example, 15-26-responders were particularly
sensitive to substitutions at position 22. It will be important to
determine whether these substitutions preclude interaction with the
TCR of these cells, or permit an antagonistic interaction, or whether
different substitutions at the same position can have different
effects. Notably, the studies by Allen's group (Evavold and Allen,
1991; Sloan-Lancaster et al., 1993) which were performed using Ek-
restricted T cells did not find any substitutions at the position
corresponding to 12-26 residue 22 which had a differential effect
on interleukin production and proliferations. And they observed that
within the limited set of peptides they identified, changes in more
permissive residues were more likely to lead to differential
signalling than those at less permissive residues. Some cells
belonging to the 15-26-responder group were nonetheless unable to
respond to analogs containing substitutions at position 14, so one
would like to know whether substitutions at this position can create
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antagonistic interactions. Perhaps the most striking result of the
fine-specificity analysis carried out in Chapter 2 was that the 15-
26-nonresponders accepted almost no substitutions at nearly all
positions. It will therefore be interesting to determine whether
these cells represent a class that is particularly susceptible to
antagonistic substitutions.
These recent results and future prospects show the potential
applications of experiments using synthetic peptides to study the T
cell response. Ultimately, studies of this kind may lead to the
rational design of peptides designed to specifically prevent the
stimulation of a given T cell, a prospect with great clinical
importance.
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